
(
  (S
    (NP
      (NP (VBN Increased) (NN interleukin-17) (NN production))
      (PP (IN via)
        (NP (DT a)
          (NP
            (NP (NN phosphoinositide) (NN 3-kinase/Akt))
            (CC and)
            (NP (JJ nuclear) (NN factor)))
          (NN κB-dependent) (NN pathway)))
      (PP (IN in)
        (NP
          (NP (NNS patients))
          (PP (IN with)
            (NP (JJ rheumatoid) (NN arthritis))))))))

(
  (S
    (NP (NN Abstract))))

(
  (S
    (S
      (NP (JJ Inflammatory) (NNS mediators))
      (VP (VBP have)
        (VP (VBN been)
          (VP (VBN recognized)
            (PP (IN as)
              (S
                (VP (VBG being)
                  (ADJP (JJ important))
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN pathogenesis))
                      (PP (IN of)
                        (NP
                          (NP (JJ rheumatoid) (NN arthritis))
                          (PRN (-LRB- -LRB-)
                            (NP (NN RA))
                            (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -17))
      (VP (VBZ is)
        (NP
          (NP (DT an) (JJ important) (NN regulator))
          (PP (IN of)
            (NP
              (NP
                (ADJP
                  (ADJP (JJ immune))
                  (CC and)
                  (ADJP (JJ inflammatory)))
                (NNS responses))
              (, ,)
              (PP (VBG including)
                (NP
                  (NP (DT the) (NN induction))
                  (PP (IN of)
                    (NP
                      (NP (JJ proinflammatory) (NNS cytokines))
                      (CC and)
                      (NP (JJ osteoclastic) (NN bone) (NN resorption)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Evidence))
        (PP (IN for)
          (NP
            (NP (DT the)
              (NP (NN expression))
              (CC and)
              (NP (JJ proinflammatory) (NN activity)))
            (PP (IN of)
              (NP (NN IL-17))))))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN demonstrated)
            (PP
              (PP (IN in)
                (NP (NN RA) (NN synovium)))
              (CC and)
              (PP (IN in)
                (NP
                  (NP (JJ animal) (NNS models))
                  (PP (IN of)
                    (NP (NN RA))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP
            (NP (DT some) (NNS cytokines))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN IL-15))
                (CC and)
                (NP (NN IL-23)))
              (-RRB- -RRB-)))
          (VP (VBP have)
            (VP (VBN been)
              (VP (VBN reported)
                (S
                  (VP (TO to)
                    (VP (VB regulate)
                      (NP (NN IL-17) (NN production))))))))))
      (, ,)
      (NP
        (NP (DT the) (JJ intracellular) (NN signaling) (NNS pathways))
        (SBAR
          (WHNP (WDT that))
          (S
            (VP (VBP regulate)
              (NP (NN IL-17) (NN production))))))
      (VP (VBP remain)
        (ADJP (JJ unknown))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ present) (NN study)))
      (, ,)
      (NP (PRP we))
      (VP (VBD investigated)
        (NP
          (NP (DT the) (NN role))
          (PP (IN of)
            (NP (DT the)
              (NP
                (NP (NN phosphoinositide) (NN 3-kinase))
                (PRN (-LRB- -LRB-)
                  (NP (NN PI3K))
                  (-RRB- -RRB-)))
              (NN /Akt) (NN pathway)))
          (PP (IN in)
            (NP
              (NP (DT the) (NN regulation))
              (PP (IN of)
                (NP
                  (NP (NN IL-17) (NN production))
                  (PP (IN in)
                    (NP (NN RA))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (JJ Peripheral) (NN blood) (JJ mononuclear) (NNS cells))
          (PRN (-LRB- -LRB-)
            (NP (NN PBMC))
            (-RRB- -RRB-)))
        (PP (IN from)
          (NP
            (NP (NNS patients))
            (PP (IN with)
              (NP
                (NP (NN RA))
                (PRN (-LRB- -LRB-)
                  (NP (NN n) (JJ =) (CD 24))
                  (-RRB- -RRB-)))))))
      (VP (VBD were)
        (VP (VBN separated) (, ,)
          (S
            (ADVP (RB then))
            (VP (VBN stimulated)
              (PP (IN with)
                (NP
                  (NP (JJ various) (NNS agents))
                  (PP (VBG including)
                    (NP
                      (NP (NN anti-CD3))
                      (, ,)
                      (NP (NN anti-CD28))
                      (, ,)
                      (NP
                        (NP (NN phytohemagglutinin))
                        (PRN (-LRB- -LRB-)
                          (NP (NN PHA))
                          (-RRB- -RRB-)))
                      (CC and)
                      (NP (JJ several)
                        (NP (JJ inflammatory) (NNS cytokines))
                        (CC and)
                        (NP (NNS chemokines))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-17) (NNS levels))
      (VP (VBD were)
        (VP (VBN determined)
          (PP (IN by)
            (NP
              (NP (JJ sandwich) (JJ enzyme-linked) (JJ immunosorbent) (NN assay))
              (CC and)
              (NP (JJ reverse) (NN transcription–polymerase) (NN chain) (NN reaction)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN production))
        (PP (IN of)
          (NP (NN IL-17))))
      (VP (VBD was)
        (ADVP (RB significantly))
        (VP (VBN increased)
          (PP (IN in)
            (NP
              (NP (NNS cells))
              (VP (VBN treated)
                (PP (IN with)
                  (NP (JJ anti-CD3) (NN antibody)))
                (PP
                  (PP (IN with))
                  (CC or)
                  (PP (IN without)
                    (NP
                      (NP
                        (NP (NN anti-CD28))
                        (CC and)
                        (NP (NN PHA)))
                      (PRN (-LRB- -LRB-)
                        (NP (NN P) (NN <) (CD 0.05))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (PP (IN Among)
      (NP (VBN tested)
        (NP
          (NP (NNS cytokines))
          (CC and)
          (NP (NNS chemokines)))))
    (, ,)
    (NP
      (NP (NN IL-15))
      (, ,)
      (NP (NN monocyte) (NN chemoattractant) (NN protein-1))
      (CC and)
      (NP (NN IL-6)))
    (VP (VBD upregulated)
      (NP
        (NP (NN IL-17) (NN production))
        (PRN (-LRB- -LRB-)
          (NP (NN P) (NN <) (CD 0.05))
          (-RRB- -RRB-)))
      (, ,)
      (SBAR (IN whereas)
        (S
          (NP
            (NP (NN tumor) (NN necrosis) (NN factor-α))
            (, ,)
            (NP (NN IL-1β))
            (, ,)
            (NP (NN IL-18))
            (CC or)
            (NP (NN transforming) (NN growth) (NN factor-β)))
          (VP (VBD did) (RB not)))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN IL-17))
        (VP (VBD was)
          (ADVP (RB also))
          (VP (VBN detected)
            (PP (IN in)
              (NP
                (NP (DT the) (NNS PBMC))
                (PP (IN of)
                  (NP
                    (NP (NNS patients))
                    (PP (IN with)
                      (NP (NN osteoarthritis))))))))))
      (, ,)
      (CC but)
      (S
        (NP (PRP$ their) (NN expression) (NNS levels))
        (VP (VBD were)
          (ADJP
            (ADJP (RB much) (JJR lower))
            (PP (IN than)
              (NP
                (NP (DT those))
                (PP (IN of)
                  (NP (NN RA) (NNS PBMC)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Anti-CD3) (NN antibody))
      (VP (VBD activated)
        (NP (DT the) (NN PI3K/Akt) (NN pathway))))
    (: ;)
    (S
      (NP
        (NP (NN activation))
        (PP (IN of)
          (NP (DT this) (NN pathway))))
      (VP (VBD resulted)
        (PP (IN in)
          (NP
            (NP (DT a) (JJ pronounced) (NN augmentation))
            (PP (IN of)
              (NP (JJ nuclear) (NN factor) (NN κB) (-LRB- -LRB-) (NN NF-κB) (-RRB- -RRB-) (JJ DNA-binding) (NN activity)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IL-17) (NN production))
        (PP (IN by)
          (NP (VBN activated) (NN RA) (NNS PBMC))))
      (VP (VBZ is)
        (VP
          (ADVP
            (ADVP (RB completely))
            (CC or)
            (ADVP (RB partly)))
          (VBN blocked)
          (PP (IN in)
            (NP
              (NP (DT the) (NN presence))
              (PP (IN of)
                (NP
                  (NP (DT the) (JJ NF-κB) (NN inhibitor) (NN pyrrolidine) (NN dithiocarbamate))
                  (CC and)
                  (NP
                    (NP (DT the) (NN PI3K/Akt) (NN inhibitor))
                    (NP
                      (NP (NN wortmannin))
                      (CC and)
                      (NP
                        (NP (NN LY294002))
                        (, ,)
                        (ADVP (RB respectively))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP
        (NP (NN inhibition))
        (PP (IN of)
          (NP
            (NP (NN activator) (NN protein-1))
            (CC and)
            (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2)))))
      (VP (VBD did) (RB not)
        (VP (VB affect)
          (NP (NN IL-17) (NN production)))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP suggest)
        (SBAR (IN that)
          (S
            (NP
              (NP (NN signal) (NN transduction) (NNS pathways))
              (ADJP (JJ dependent)
                (PP (IN on)
                  (NP
                    (NP (NN PI3K/Akt))
                    (CC and)
                    (NP (NN NF-κB))))))
            (VP (VBP are)
              (VP (VBN involved)
                (PP (IN in)
                  (NP
                    (NP (DT the) (NN overproduction))
                    (PP (IN of)
                      (NP
                        (NP (DT the) (JJ key) (JJ inflammatory) (NN cytokine) (NN IL-17))
                        (PP (IN in)
                          (NP (NN RA)))))))))))))
    (. .)))

(
  (S
    (NP (NN Introduction))))

(
  (S
    (S
      (NP
        (NP (JJ Rheumatoid) (NN arthritis))
        (PRN (-LRB- -LRB-)
          (NP (NN RA))
          (-RRB- -RRB-)))
      (VP (VBZ is)
        (VP (VBN characterized)
          (PP (IN by)
            (NP
              (NP
                (NP (NNS infiltrations))
                (PP (IN of)
                  (NP
                    (NP (NNS macrophages))
                    (CC and)
                    (NP (NN T) (NNS cells))))
                (PP (IN into)
                  (NP (DT the) (NN joint))))
              (, ,)
              (CC and)
              (NP (JJ synovial) (NN hyperplasia)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Proinflammatory) (NNS cytokines))
        (VP (VBN released)
          (PP (IN from)
            (NP (DT these) (NNS cells)))))
      (VP (VBP are)
        (VP (VBN known)
          (S
            (VP (TO to)
              (VP (VB be)
                (ADJP (JJ important)
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN destruction))
                      (PP (IN of)
                        (NP (NNS joints)))
                      (PP (IN in)
                        (NP (NN RA) (NN -LSB-1) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ favorable) (JJ clinical) (NNS benefits))
        (VP (VBN obtained)
          (PP (IN with)
            (NP
              (NP (NNS inhibitors))
              (PP (IN of)
                (NP
                  (NP
                    (NP (NN tumor) (NN necrosis) (NN factor))
                    (PRN (-LRB- -LRB-)
                      (NP (NN TNF) (-RRB- -RRB-) (CD -α))
                      (-RRB- -RRB-)))
                  (CC and)
                  (NP (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -1))))))))
      (VP (VBP suggest)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT the) (NN blockade))
              (PP (IN of)
                (NP (JJ key) (JJ inflammatory) (NNS cytokines))))
            (VP (VBZ has)
              (VP (VBN been)
                (NP (DT the) (JJ important) (NN issue))
                (PP (IN in)
                  (NP
                    (NP (DT the) (NN development))
                    (PP (IN of)
                      (NP
                        (NP (JJ new) (JJ therapeutic) (NNS applications))
                        (PRN (NN -LSB-2) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (DT A)
            (ADJP (JJ little)
              (PP (IN over)
                (NP
                  (NP (DT a) (NN decade))
                  (ADVP (RB ago))))))
          (, ,)
          (NP
            (NP (DT the) (NN primacy))
            (PP (IN of)
              (NP (NN T) (NNS cells)))
            (PP (IN in)
              (NP
                (NP (DT the) (NN pathogenesis))
                (PP (IN of)
                  (NP (JJ autoimmune) (NN disease)))))))
        (PP (JJ such) (IN as)
          (NP (NN RA))))
      (VP (VBD was)
        (VP (VBN undisputed)
          (SBAR (IN because)
            (S
              (NP (PRP they))
              (VP (VBP are)
                (NP
                  (NP (DT the) (JJS largest) (NN cell) (NN population))
                  (VP (VBG infiltrating)
                    (NP (DT the) (NN synovium))))))))))
    (. .)))

(
  (S
    (ADVP (RB However))
    (, ,)
    (NP
      (NP (DT a) (NN series))
      (PP (IN of)
        (NP (NNS studies))))
    (VP (VBD demonstrated)
      (NP
        (NP (NN paucity))
        (PP (IN of)
          (NP
            (NP (NN T) (JJ cell-derived) (NNS cytokines))
            (PP (JJ such) (IN as)
              (NP
                (NP
                  (NP (NN IL-2))
                  (CC and)
                  (NP (NN interferon-γ)))
                (PP (IN in)
                  (NP
                    (NP (DT the) (NNS joints))
                    (PP (IN of)
                      (NP (NN RA))))))))))
      (, ,)
      (SBAR (IN whereas)
        (S
          (NP
            (NP (NN macrophage)
              (CC and)
              (NN fibroblast) (NNS cytokines))
            (PP (VBG including)
              (NP
                (NP (NN IL-1))
                (, ,)
                (NP (NN IL-6))
                (, ,)
                (NP (NN IL-15))
                (, ,)
                (NP (NN IL-18))
                (CC and)
                (NP (NN TNF-α)))))
          (VP (VBD were)
            (ADJP (JJ abundant)
              (PP (IN in)
                (NP (JJ rheumatoid) (NN synovium))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN paradox))
      (VP (VBZ has)
        (VP (VBN questioned)
          (NP
            (NP (DT the) (NN role))
            (PP (IN of)
              (NP (NN T) (NNS cells)))
            (PP (IN in)
              (NP
                (NP (DT the) (NN pathogenesis))
                (PP (IN of)
                  (NP (NN RA) (NN -LSB-3))))))
          (-RRB- -RSB-))))
    (. .)))

(
  (S
    (SBAR (IN Because)
      (S
        (NP (PRP we))
        (VP (VBP have)
          (ADVP (RB already))
          (VP (VBN demonstrated)
            (NP
              (NP
                (NP (DT the) (VBN enhanced) (NN proliferation))
                (PP (IN of)
                  (NP
                    (NP (NN antigen) (JJ specific) (NN T) (NNS cells))
                    (, ,)
                    (ADVP (RB especially))))
                (PP (TO to)
                  (NP (NN type) (CD II) (NN collagen))))
              (, ,)
              (CC and)
              (NP
                (NP (DT the) (NN skewing))
                (PP (IN of)
                  (NP (NN T) (NN helper) (NN type) (CD 1) (-LRB- -LRB-) (NN Th1) (-RRB- -RRB-) (NNS cytokines)))
                (PP (IN in)
                  (NP (NN RA) (NN -LSB-4))))
              (-RRB- -RSB-))))))
    (, ,)
    (NP
      (NP (DT the) (NN role))
      (PP (IN of)
        (NP (NN T) (NNS cells))))
    (VP (VBZ needs)
      (S
        (VP (TO to)
          (VP (VB be)
            (VP (VBN elucidated)
              (PP (IN in)
                (NP (JJ different) (NNS aspects))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-17))
      (VP (VBZ is)
        (NP
          (NP (CD one))
          (PP (IN of)
            (NP
              (NP (DT the) (JJ inflammatory) (NNS cytokines))
              (VP (VBN secreted)
                (ADVP (RB mainly))
                (PP (IN by)
                  (NP (VBN activated) (NN T) (NNS cells)))))))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (MD can)
              (VP (VB induce)
                (NP
                  (NP (NN IL-6))
                  (CC and)
                  (NP (NN IL-8)))
                (PP (IN by)
                  (NP (NNS fibroblasts) (CD -LSB-5) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN cytokine))
      (VP (VBZ is)
        (PP (IN of)
          (NP (NN interest)))
        (PP (IN for)
          (NP (CD two) (JJ major) (NNS reasons)))))
    (: :)
    (S
      (ADVP (RB first))
      (, ,)
      (PP
        (ADVP (RB similarly))
        (TO to)
        (NP
          (NP (NN TNF-α))
          (CC and)
          (NP (NN IL-1))))
      (, ,)
      (NP (NN IL-17))
      (VP (VBZ has)
        (NP (JJ proinflammatory) (NNS properties))))
    (: ;)
    (S
      (ADVP (RB second))
      (, ,)
      (NP (PRP it))
      (VP (VBZ is)
        (VP (VBN produced)
          (PP (IN by)
            (NP (NN T) (NNS cells) (CD -LSB-6) (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (NP (JJ Recent) (NNS observations))
    (VP (VBD demonstrated)
      (SBAR (IN that)
        (S
          (NP (NN IL-17))
          (VP (MD can)
            (ADVP (RB also))
            (VP (VB activate)
              (NP (JJ osteoclastic) (NN bone) (NN resorption))
              (PP (IN by)
                (NP
                  (NP (DT the) (NN induction))
                  (PP (IN of)
                    (NP
                      (NP
                        (NP (NN RANKL))
                        (PRN (-LRB- -LRB-)
                          (NP
                            (NP (NN receptor) (NN activator))
                            (PP (IN of)
                              (NP (JJ nuclear) (NN factor) (NN κB) (NN -LSB-NF-κB) (-RRB- -RSB-) (NN ligand))))
                          (-RRB- -RRB-)))
                      (, ,)
                      (SBAR
                        (WHNP (WDT which))
                        (S
                          (VP (VBZ is)
                            (VP (VBN involved)
                              (PP (IN in)
                                (NP (NN bony) (NN erosion)))
                              (PP (IN in)
                                (NP (NN RA) (NN -LSB-7) (-RRB- -RSB-))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (ADVP (RB also))
      (VP
        (VP (VBZ stimulates)
          (NP
            (NP (DT the) (NN production))
            (PP (IN of)
              (NP
                (NP (NN IL-6))
                (CC and)
                (NP (NN leukemia) (JJ inhibitory) (NN factor))))
            (PP
              (PP (IN by)
                (NP (NNS synoviocytes)))
              (, ,)
              (CC and)
              (PP (IN of)
                (NP
                  (NP (NN prostaglandin) (NN E2))
                  (CC and)
                  (NP (JJ nitric) (NN oxide))))
              (PP (IN by)
                (NP (NNS chondrocytes))))))
        (, ,)
        (CC and)
        (VP (VBZ has)
          (NP (DT the) (NN ability)
            (S
              (VP (TO to)
                (VP
                  (VP (VB differentiate))
                  (CC and)
                  (VP (VB activate)
                    (NP
                      (NP (DT the) (JJ dendritic) (NNS cells))
                      (CD -LSB-8-10) (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (NNS Levels))
          (PP (IN of)
            (NP (NN IL-17)))
          (PP (IN in)
            (NP (JJ synovial) (NNS fluids))))
        (VP (VBD were)
          (ADJP
            (ADJP (RB significantly) (JJR higher))
            (PP (IN in)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP (NN RA)))))
            (PP (IN than)
              (PP (IN in)
                (NP
                  (NP (NNS patients))
                  (PP (IN with)
                    (NP
                      (NP (NN osteoarthritis))
                      (PRN (-LRB- -LRB-)
                        (NP (NN OA))
                        (-RRB- -RRB-))))))))))
      (, ,)
      (CC and)
      (S
        (NP (PRP it))
        (VP (VBD was)
          (VP (VBN produced)
            (PP (IN by)
              (NP (JJ CD4+) (NN T) (NNS cells)))
            (PP (IN in)
              (NP (DT the) (NN synovium) (NN -LSB-11,12)))))
        (-RRB- -RSB-)))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IL-15))
        (, ,)
        (VP (VBN secreted)
          (PP (IN from)
            (NP (VBN activated) (NNS macrophages))))
        (, ,))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN reported)
            (S
              (VP (TO to)
                (VP (VB be)
                  (NP
                    (NP (DT an) (JJ important) (NN trigger))
                    (PP (IN of)
                      (NP
                        (NP (NN IL-17) (NN production))
                        (PP (IN in)
                          (NP
                            (NP (NN RA) (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
                            (PRN (-LRB- -LRB-)
                              (NP (NN PBMC))
                              (-RRB- -RRB-))))
                        (PP (IN by)
                          (NP
                            (NP (NN cyclosporine))
                            (CC and)
                            (NP (NN steroid) (JJ sensitive) (NNS pathways))
                            (NP (NN -LSB-13))
                            (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (ADVP (RB Recently))
    (, ,)
    (NP
      (NP (NN Happel))
      (CC and)
      (NP (NNS colleagues)))
    (ADVP (RB also))
    (VP (VBD showed)
      (SBAR (IN that)
        (S
          (NP (NN IL-23))
          (VP (MD could)
            (VP (VB be)
              (NP
                (NP (DT an) (JJ efficient) (NN trigger))
                (PP (IN of)
                  (NP
                    (NP (NN IL-17) (NN production))
                    (PP (IN from)
                      (NP
                        (ADJP (CC both)
                          (ADJP (JJ CD4+))
                          (CC and)
                          (ADJP (JJ CD8+)))
                        (NN T) (NNS cells)
                        (NP (CD -LSB-14)))))))))
          (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP
            (NP (DT the) (NN contribution))
            (PP (IN of)
              (NP (NN IL-17)))
            (PP (IN in)
              (NP
                (NP (NN joint) (NN inflammation))
                (PP (IN in)
                  (NP (NN RA))))))
          (VP (VBZ has)
            (VP (VBN been)
              (VP (VBN documented)
                (PP (IN in)
                  (NP (JJR earlier) (NNS studies)
                    (NP (CD -LSB-12,15,16)))))))
          (-RRB- -RSB-)))
      (, ,)
      (NP
        (NP (DT the) (JJ intracellular) (NN signal) (NN transduction) (NN pathway))
        (PP (IN for)
          (NP (NN IL-17) (NN production))))
      (VP (VBZ remains)
        (ADJP (JJ uncertain))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ present) (NN study)))
      (NP (PRP we))
      (VP (VBD used)
        (NP (JJ various) (NNS stimuli))
        (S
          (VP (TO to)
            (VP (VB investigate)
              (NP
                (NP
                  (NP (NN IL-17) (NN production))
                  (PP (IN in)
                    (NP
                      (NP (NN PBMC))
                      (PP (IN of)
                        (NP
                          (NP (NNS patients))
                          (PP (IN with)
                            (NP (NN RA))))))))
                (CC and)
                (NP (PRP$ its) (NN signaling) (NN transduction) (NN pathway))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD found)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT the) (JJ intracellular) (NN signaling) (NN pathway))
              (VP (VBG involving)
                (NP
                  (NP
                    (NP
                      (NP (NN phosphoinositide) (NN 3-kinase))
                      (PRN (-LRB- -LRB-)
                        (NP (NN PI3K))
                        (-RRB- -RRB-)))
                    (NN /Akt))
                  (CC and)
                  (NP (NN NF-κB)))))
            (VP (MD might)
              (VP (VB be)
                (VP (VBN involved)
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN overproduction))
                      (PP (IN of)
                        (NP
                          (NP (DT the) (JJ key) (JJ inflammatory) (NN cytokine) (NN IL-17))
                          (PP (IN in)
                            (NP (NN RA))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (MD might)
        (VP (VB provide)
          (NP
            (NP
              (NP (JJ new) (NNS insights))
              (PP (IN into)
                (NP
                  (NP (DT the) (NN pathogenesis))
                  (PP (IN of)
                    (NP (NN RA))))))
            (CC and)
            (NP
              (NP (JJ future) (NNS directions))
              (PP (IN for)
                (NP
                  (NP (JJ new) (JJ therapeutic) (NNS strategies))
                  (PP (IN in)
                    (NP (NN RA))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Materials))
      (CC and)
      (NP (NNS methods)))))

(
  (S
    (S
      (NP (VBN Informed) (NN consent))
      (VP (VBD was)
        (VP (VBN obtained)
          (PP (IN from)
            (NP
              (NP
                (NP (CD 24) (NNS patients))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (CD 5) (NNS men))
                    (CC and)
                    (NP (CD 19) (NNS women)))
                  (-RRB- -RRB-)))
              (PP (IN with)
                (NP (NN RA)))
              (SBAR
                (WHNP (WP who))
                (S
                  (VP (VBD fulfilled)
                    (NP
                      (NP (DT the) (CD 1987) (JJ revised) (NNS criteria))
                      (PP (IN of)
                        (NP
                          (NP (DT the) (NNP American) (NNP College))
                          (PP (IN of)
                            (NP (NN Rheumatology))))))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (ADVP (RB formerly))
                        (NP (DT the)
                          (NP (NNP American))
                          (NN Rheumatism) (NN Association)))
                      (-RRB- -RRB-)
                      (NP (CD -LSB-17))
                      (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN age))
        (PP (IN of)
          (NP
            (NP (DT the) (NNS patients))
            (PP (IN with)
              (NP (NN RA))))))
      (VP (VBD was)
        (NP
          (NP
            (QP (CD 50) (CD ±) (CD 8)
              (PRN (-LRB- -LRB-)
                (NP (NN mean) (NN ±) (NN SEM))
                (-RRB- -RRB-)))
            (NNS years))
          (PRN (-LRB- -LRB-)
            (NP (NN range) (CD 23–71) (NNS years))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NNS medications))
      (VP (VBD were)
        (VP (VBN stopped)
          (PP
            (NP (CD 48) (NNS hours))
            (IN before)
            (NP
              (NP (NN entry))
              (PP (TO to)
                (NP (DT the) (NN study))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Comparisons))
      (VP (VBD were)
        (VP (VBN made)
          (PP
            (PP (IN with)
              (NP
                (NP
                  (NP (CD 14) (NNS patients))
                  (PP (IN with)
                    (NP (NN OA))))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (CD 3) (NNS men))
                    (CC and)
                    (NP (CD 11) (NNS women)))
                  (-RRB- -RRB-))))
            (CC and)
            (PP (IN with)
              (NP
                (NP
                  (NP (CD 14) (JJ healthy) (NNS controls))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (CD 3) (NNS men))
                      (CC and)
                      (NP (CD 11) (NNS women)))
                    (-RRB- -RRB-)))
                (SBAR
                  (WHNP (WP who))
                  (S
                    (VP (VBD had)
                      (NP (DT no) (JJ rheumatic) (NNS diseases)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ mean) (NNS ages))
        (PP (IN of)
          (NP
            (NP
              (NP (DT the) (NNS patients))
              (PP (IN with)
                (NP (NN OA))))
            (CC and)
            (NP (DT the) (JJ healthy) (NNS controls)))))
      (VP (VBD were)
        (NP
          (NP
            (NP (CD 50) (NN ±) (CD 8) (NNS years))
            (PRN (-LRB- -LRB-)
              (NP (NN range) (CD 34–68) (NNS years))
              (-RRB- -RRB-)))
          (CC and)
          (NP
            (NP (CD 30) (NN ±) (CD 6) (NNS years))
            (PRN (-LRB- -LRB-)
              (NP (NN range) (CD 24–57) (NNS years))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (VBN Informed) (NN consent))
        (VP (VBD was)
          (VP (VBN obtained))))
      (, ,)
      (CC and)
      (S
        (NP (DT the) (NN protocol))
        (VP (VBD was)
          (ADJP (JJ approved)
            (PP (IN by)
              (NP
                (NP (DT the) (JJ Catholic) (NNP University))
                (PP (IN of)
                  (NP
                    (NP (NNP Korea))
                    (NP (JJ Human) (NN Research) (NNP Ethics) (NNP Committee))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Recombinant) (NN IL-17))
        (, ,)
        (NP (NN IL-18))
        (, ,)
        (NP (NN IL-15))
        (, ,)
        (NP
          (NP (NN monocyte) (NN chemoattractant) (NN protein-1))
          (PRN (-LRB- -LRB-)
            (NP (NN MCP-1))
            (-RRB- -RRB-)))
        (, ,)
        (NP (NN macrophage) (JJ inflammatory) (NN protein) (-LRB- -LRB-) (NN MIP) (-RRB- -RRB-) (CD -1α))
        (, ,)
        (NP (NN MIP-1β))
        (, ,)
        (NP (NN IL-6))
        (CC and)
        (NP (NN IL-8)))
      (VP (VBD were)
        (VP (VBN purchased)
          (PP (IN from)
            (NP
              (NP (NN R) (NN &) (NN D) (NNS systems))
              (PRN (-LRB- -LRB-)
                (NP (NNP Minneapolis) (, ,) (NN MN) (, ,) (NN USA))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Recombinant)
        (NP
          (NP (NN transforming) (NN growth) (NN factor))
          (PRN (-LRB- -LRB-)
            (NP (NN TGF))
            (-RRB- -RRB-)))
        (NN -β))
      (VP (VBD was)
        (VP (VBN purchased)
          (PP (IN from)
            (NP
              (NP (NNP Peprotech))
              (PRN (-LRB- -LRB-)
                (NP (NNP London) (, ,) (NNP UK))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Recombinant) (NN TNF-α))
        (CC and)
        (NP (NN IL-1)))
      (VP (VBD were)
        (VP (VBN purchased)
          (PP (IN from)
            (NP
              (NP (NNP Endogen) (NNP Inc.))
              (PRN (-LRB- -LRB-)
                (NP (NN Cambridge))
                (, ,)
                (NP
                  (NP (NN MA))
                  (, ,)
                  (NP (NN USA)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN Cyclosporin) (NN A))
      (VP (VBD was)
        (VP (VBN provided)
          (PP (IN by)
            (NP
              (NP (NNP Sandos) (NNP Ltd.))
              (PRN (-LRB- -LRB-)
                (NP (NNP Basel) (, ,) (NNP Switzerland))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN Phytohemagglutinin))
          (PRN (-LRB- -LRB-)
            (NP (NN PHA))
            (-RRB- -RRB-)))
        (, ,)
        (NP
          (NP (NN pyrrolidine) (NN dithiocarbamate))
          (PRN (-LRB- -LRB-)
            (NP (NN PDTC))
            (-RRB- -RRB-)))
        (, ,)
        (NP (NN rapamycin))
        (, ,)
        (NP (NN dexamethasone))
        (CC and)
        (NP (NN curcumin)))
      (VP (VBD were)
        (ADVP (RB all))
        (VP (VBN obtained)
          (PP (IN from)
            (NP (DT the) (NN Sigma) (JJ Chemical) (NN Co.))))))
    (. .)))

(
  (S
    (S
      (PRN (-LRB- -LRB-)
        (NP
          (NP (JJ St) (NN Louis))
          (, ,)
          (NP (NN MA))
          (, ,)
          (NP (NN USA)))
        (-RRB- -RRB-)))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Anti-CD3) (JJ monoclonal) (NN antibody))
        (CC and)
        (NP (JJ anti-CD28) (JJ monoclonal) (NN antibody)))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN from)
            (NP
              (NP (NNP BD) (NNP Biosciences))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP
                    (NP (NNP San) (NNP Diego))
                    (, ,)
                    (NP (NN CA)))
                  (, ,)
                  (NP (NNP USA)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN LY294002))
        (, ,)
        (NP (NN SB203580))
        (, ,)
        (NP (NN FK506))
        (, ,)
        (NP (NN wortmannin))
        (CC and)
        (NP (NN PD98059)))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN from)
            (NP
              (NP (NNP Calbiochem))
              (PRN (-LRB- -LRB-)
                (NP (NNP Schwalbach) (, ,) (NNP Germany))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBD were)
        (VP (VBN prepared)
          (PP (IN from)
            (NP (JJ heparinized) (NN blood)))
          (PP (IN by)
            (NP (NN Ficoll-Hypaque) (-LRB- -LRB-) (CD SG1077) (-RRB- -RRB-) (JJ density-gradient) (NN centrifugation))))))
    (. .)))

(
  (S
    (S
      (NP (NN Cell) (NNS cultures))
      (VP (VBD were)
        (VP (VBN performed)
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (ADVP (RB previously))
                (S
                  (NP (NN -LSB-18))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (JJ brief)))
      (, ,)
      (NP (DT the) (NN cell) (NNS suspensions))
      (VP (VBD were)
        (VP (VBN adjusted)
          (PP (TO to)
            (NP
              (NP (DT a) (NN concentration))
              (PP (IN of)
                (NP (NN 106/ml)))
              (PP (IN in)
                (NP
                  (NP (NN RPMI) (CD 1640) (NN medium))
                  (VP (VBN supplemented)
                    (PP (IN with)
                      (NP
                        (NP
                          (ADJP (CD 10) (NN %))
                          (JJ fetal) (NN calf) (NN serum))
                        (, ,)
                        (NP
                          (ADJP (CD 100) (NN U/ml))
                          (NN penicillin))
                        (, ,)
                        (NP
                          (ADJP (CD 100) (NN mg/ml))
                          (NN streptomycin))
                        (CC and)
                        (NP
                          (ADJP (CD 2) (NN mM))
                          (NN L-glutamine))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Cell) (NN suspension))
        (PRN (-LRB- -LRB-)
          (NP (CD 1) (NN ml))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (VP
          (VP (VBN dispensed)
            (PP (IN into)
              (NP
                (NP (JJ 24-well) (JJ multi-well) (NNS plates))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Nunc) (, ,) (NNP Roskilde) (, ,) (NNP Denmark))
                  (-RRB- -RRB-)))))
          (, ,)
          (CC and)
          (VP (VBN incubated)
            (PP (IN for)
              (NP (CD 24) (NNS hours)))
            (PP (IN at)
              (NP (NN 37°C)))
            (PP (IN in)
              (NP
                (ADJP (CD 5) (NN %))
                (NN CO2)))))))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB Subsequently))
        (, ,)
        (NP
          (NP (JJ various) (NNS concentrations))
          (PP (IN of)
            (NP
              (NP (NN cyclosporin) (NN A))
              (PRN (-LRB- -LRB-)
                (NP (CD 10–500) (NN ng/ml))
                (-RRB- -RRB-)))))
        (VP (VBD were)
          (VP (VBN added)
            (PP (TO to)
              (NP (DT the) (NN medium))))))
      (CC and)
      (S
        (NP (NNS cells))
        (VP (VBD were)
          (VP (VBN incubated)
            (PP (IN for)
              (NP (CD 24) (NNS hours)))))))
    (. .)))

(
  (S
    (S
      (PP (TO To)
        (NP (DT each) (NN well)))
      (VP (VBD was)
        (VP (VBN added)
          (NP
            (NP (NN FK506))
            (, ,)
            (NP (NN rapamycin))
            (, ,)
            (NP (NN curcumin))
            (, ,)
            (NP (NN PDTC))
            (, ,)
            (NP
              (NP (NN LY294002))
              (, ,)
              (NP (NN SB203580))
              (, ,)
              (NP (NN PD98059))
              (, ,)
              (NP (NN dexamethasone))
              (CC or)
              (NP (NN wortmannin)))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN incubation))
          (PP (IN for)
            (NP
              (NP (CD 24) (NNS hours))
              (PRN (-LRB- -LRB-)
                (SBAR (IN unless)
                  (S
                    (ADVP (RB otherwise))
                    (VP (VBN stated))))
                (-RRB- -RRB-))))))
      (, ,)
      (NP (JJ cell-free) (NNS media))
      (VP (VBD were)
        (VP
          (VP (VBN collected))
          (CC and)
          (VP (VBN stored)
            (PP (IN at)
              (NP (NN -20°C)))
            (SBAR (IN until)
              (S
                (VP (VBN assayed))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (DT All) (NNS cultures))
        (VP (VBD were)
          (VP (VBN set)
            (PRT (RP up))
            (PP (IN in)
              (NP (NN triplicate))))))
      (, ,)
      (CC and)
      (S
        (NP (NNS results))
        (VP (VBP are)
          (VP (VBN expressed)
            (PP (IN as)
              (NP
                (NP (NNS means))
                (VP (VBG ±)
                  (NP (NN SEM)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Anti-CD4) (NNS microbeads))
      (VP (VBD were)
        (VP (VBN used)
          (ADVP (RB essentially))
          (SBAR (IN as)
            (S
              (VP (VBN recommended)
                (PP (IN by)
                  (NP (DT the) (NN manufacturer)))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Miltenyi) (-RRB- -RRB-) (CD -LSB-19))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBD were)
        (VP (VBN resuspended)
          (PP (IN in)
            (NP
              (NP (CD 80) (NN μl))
              (PP (IN of)
                (NP
                  (NP (NNS FBS))
                  (VP (VBG staining)
                    (NP (NN buffer))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Anti-CD4) (NNS microbeads))
        (PRN (-LRB- -LRB-)
          (NP (CD 20) (NN μl))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP
          (VP (VBN added))
          (CC and)
          (VP (VBN incubated)
            (PP (IN for)
              (NP (CD 15) (NN min)))
            (PP (IN at)
              (NP (NN 6–12°C)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Saturating) (NNS amounts))
        (PP (IN of)
          (NP (JJ fluorochrome-conjugated) (NNS antibodies))))
      (VP (VBD were)
        (VP (VBN added)
          (PP (IN for)
            (NP (DT a) (JJ further) (CD 10) (NN min))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Cells))
      (VP (VBD were)
        (VP
          (VP (VBN diluted)
            (PP (IN in)
              (NP
                (NP (CD 2.5) (NN ml))
                (PP (IN of)
                  (NP
                    (NP (NNS FBS))
                    (VP (VBG staining)
                      (NP (NN buffer))))))))
          (, ,)
          (VP (VBN pelleted))
          (, ,)
          (VP (VBN resuspended)
            (PP (IN in)
              (NP (CD 500) (NN μl))))
          (CC and)
          (ADVP (RB magnetically))
          (VP (VBN separated)))
        (, ,)
        (ADVP (RB usually))
        (PP (IN on)
          (NP
            (NP (DT an) (NN AutoMACS) (NN magnet))
            (VP (VBN fitted)
              (PP (IN with)
                (NP (DT a) (NN MACS) (NN MS) (NN column))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (ADJP (JJ Flow-through)))
        (CC and)
        (NP (CD two)
          (ADJP (CD 1) (NN ml))
          (NNS washes)))
      (VP (VBD were)
        (VP (VBN collected)
          (PP (IN as)
            (NP (DT the) (JJ negative) (NN fraction))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Enriched) (NNS cells))
      (VP (VBD were)
        (VP (VBN collected)
          (PP (IN in)
            (NP
              (NP (CD two)
                (ADJP (CD 0.5) (NN ml))
                (NNS aliquots))
              (PP (IN from)
                (NP (DT the) (NN column)))))
          (PP (IN after)
            (NP
              (NP (NN removal))
              (PP (IN from)
                (NP (DT the) (NN magnet))))))))
    (. .)))

(
  (S
    (ADVP (RB Alternatively))
    (, ,)
    (NP
      (NP (NNS cells))
      (VP (VBN stained)
        (PP (IN with)
          (NP (NN anti-CD4–phycoerythrin)))))
    (VP (VBD were)
      (VP
        (VP (VBN washed))
        (, ,)
        (VP
          (ADVP (RB magnetically))
          (VBN labeled)
          (PP (IN with)
            (NP
              (NP (JJ anti-phycoerythrin) (NNS microbeads))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (CD 20) (NN μl))
                  (VP (VBN added)
                    (PP (TO to)
                      (NP
                        (NP (CD 80) (NN μl))
                        (PP (IN of)
                          (NP (NN cell) (NN suspension)))))))
                (: ;)
                (NP (CD 15) (NN min))
                (, ,)
                (NP (NNS 6–12°C))
                (-RRB- -RRB-)))))
        (, ,)
        (CC and)
        (ADVP (RB magnetically))
        (VP (VBN separated)
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (ADVP (RB above))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN purity))
        (PP (IN of)
          (NP (NNS cells))))
      (VP (VBD was)
        (VP (VBN assessed)
          (PP (IN by)
            (NP
              (NP
                (ADJP (NN flow) (JJ cytometric))
                (NN analysis))
              (PP (IN of)
                (NP
                  (NP (VBN stained) (NNS cells))
                  (PP (IN on)
                    (NP (DT a) (NN FACS) (NN Vantage) (NN sorter))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (JJS Most))
          (PRN (-LRB- -LRB-)
            (NP
              (QP (JJR more) (IN than) (CD 97))
              (NN %))
            (-RRB- -RRB-)))
        (PP (IN of)
          (NP (DT the) (VBN isolated) (NNS cells))))
      (VP (VBD had)
        (NP (DT the) (NN CD4) (NN T) (NN cell) (NN marker))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IL-17))
        (PP (IN in)
          (NP (NN culture) (NNS supernatants))))
      (VP (VBD was)
        (VP (VBN measured)
          (PP (IN by)
            (NP (JJ sandwich) (JJ enzyme-linked) (JJ immunosorbent) (NN assay)))
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (ADVP (RB previously))
                (PRN
                  (QP (CD -LSB-20))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (JJ brief)))
    (, ,)
    (NP
      (NP (DT a) (JJ 96-well) (NN plate))
      (PRN (-LRB- -LRB-)
        (NP (NN Nunc))
        (-RRB- -RRB-)))
    (VP (VBD was)
      (VP (VBN coated)
        (PP (IN with)
          (NP
            (NP (CD 4) (NN μg/ml) (JJ monoclonal) (NNS antibodies))
            (PP (IN against)
              (NP (NN IL-17)))))
        (PRN (-LRB- -LRB-)
          (NP (NN R) (NN &) (NN D) (NNS Systems))
          (-RRB- -RRB-))
        (PP (IN at)
          (NP (JJ 4°C) (JJ overnight)))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (NN blocking))
        (PP (IN with)
          (NP
            (NP (JJ phosphate-buffered) (NN saline/1) (NN %) (JJ bovine) (NN serum) (NN albumin))
            (PRN (-LRB- -LRB-)
              (NP (NN BSA))
              (-RRB- -RRB-))))))
    (NP (CD /0.05) (NN %))))

(
  (S
    (S
      (PP
        (NP (NNP Tween) (CD 20))
        (IN for)
        (NP
          (NP (CD 2) (NNS hours))
          (PP (IN at)
            (NP
              (NP (JJ room) (NN temperature))
              (PRN (-LRB- -LRB-)
                (NP (NN 22–25°C))
                (-RRB- -RRB-))))))
      (, ,)
      (NP
        (NP (NN test) (NNS samples))
        (CC and)
        (NP
          (NP (DT the) (JJ standard) (JJ recombinant) (NN IL-17))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NN R))
              (NP (NN &) (NN D) (NNS Systems)))
            (-RRB- -RRB-))))
      (VP (VBD were)
        (VP
          (VP (VBN added)
            (PP (TO to)
              (NP (DT the) (JJ 96-well) (NN plate))))
          (CC and)
          (VP (VBN incubated)
            (PP (IN at)
              (NP (JJ room) (NN temperature)))
            (PP (IN for)
              (NP (CD 2) (NNS hours)))))))
    (. .)))

(
  (S
    (NP (NNS Plates))
    (VP (VBD were)
      (VP
        (VP (VBN washed)
          (NP (CD four) (NNS times))
          (PP (IN with)
            (NP (JJ phosphate-buffered) (NN saline/Tween) (CD 20))))
        (, ,)
        (CC and)
        (ADVP (RB then))
        (VP (VBN incubated)
          (PP (IN with)
            (NP
              (NP
                (ADJP
                  (NP (CD 500) (NN ng/ml))
                  (VBN biotinylated))
                (NN mouse) (JJ monoclonal) (NNS antibodies))
              (PP (IN against)
                (NP
                  (NP (NN IL-17))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN R))
                      (NP (NN &) (NN D) (NNS Systems)))
                    (-RRB- -RRB-))))))
          (PP (IN for)
            (NP (CD 2) (NNS hours)))
          (PP (IN at)
            (NP (JJ room) (NN temperature))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (VBG washing)))
      (, ,)
      (NP
        (NP
          (NP (NN streptavidin–alkaline) (NN phosphate–horseradish) (NN peroxidase))
          (NN conjugate))
        (PRN (-LRB- -LRB-)
          (NP (NN Sigma))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (VP (VBN incubated)
          (PP (IN for)
            (NP (CD 2) (NNS hours)))
          (, ,)
          (ADVP (RB then))
          (VP
            (VP (VBN washed)
              (ADVP (RB again)))
            (CC and)
            (VP (VBN incubated)
              (PP (IN with)
                (NP
                  (NP
                    (NP (CD 1) (NN mg/ml) (NN p-nitrophenyl) (NN phosphate))
                    (PRN (-LRB- -LRB-)
                      (NP (NN Sigma))
                      (-RRB- -RRB-)))
                  (VP (VBN dissolved)
                    (PP (IN in)
                      (NP
                        (NP (NN diethanolamine))
                        (PRN (-LRB- -LRB-)
                          (NP (NN Sigma))
                          (-RRB- -RRB-))))
                    (S
                      (VP (TO to)
                        (VP (VB develop)
                          (NP (DT the) (NN color) (NN reaction)))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (DT The) (NN reaction))
        (VP (VBD was)
          (VP (VBN stopped)
            (PP (IN by)
              (NP
                (NP (DT the) (NN addition))
                (PP (IN of)
                  (NP
                    (ADJP (CD 1) (NN M))
                    (NN NaOH))))))))
      (CC and)
      (S
        (NP
          (NP (DT the) (JJ optical) (NN density))
          (PP (IN of)
            (NP (DT each) (NN well))))
        (VP (VBD was)
          (VP (VBN read)
            (PP (IN at)
              (NP (CD 405) (NN nm)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJR lower) (NN limit))
        (PP (IN of)
          (NP (NN IL-17) (NN detection))))
      (VP (VBD was)
        (NP (CD 10) (NN pg/ml))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Recombinant) (JJ human) (NN IL-17))
        (VP (VBN diluted)
          (PP (IN in)
            (NP (NN culture) (NN medium)))))
      (VP (VBD was)
        (VP (VBN used)
          (PP (IN as)
            (NP
              (NP (DT a) (JJ calibration) (JJ standard))
              (, ,)
              (VP (VBG ranging)
                (PP (IN from)
                  (NP
                    (QP (CD 10) (TO to) (CD 2000))
                    (NN pg/ml)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT A) (JJ standard) (NN curve))
      (VP (VBD was)
        (VP
          (VP (VBN drawn)
            (PP (IN by)
              (S
                (VP (VBG plotting)
                  (NP (NN optical) (NN density))
                  (PP (IN against)
                    (NP
                      (NP (DT the) (NN log))
                      (PP (IN of)
                        (NP
                          (NP (DT the) (NN concentration))
                          (PP (IN of)
                            (NP (JJ recombinant) (NNS cytokines)))))))))))
          (, ,)
          (CC and)
          (VP (VBN used)
            (PP (IN for)
              (NP
                (NP (NN determination))
                (PP (IN of)
                  (NP
                    (NP (NN IL-17))
                    (PP (IN in)
                      (NP (NN test) (NNS samples)))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN with)
            (NP
              (NP (JJ various) (NNS concentrations))
              (PP (IN of)
                (NP (NN anti-CD3)))))
          (PP (IN in)
            (NP
              (NP (DT the)
                (NP (NN presence))
                (CC or)
                (NP (NN absence)))
              (PP (IN of)
                (NP
                  (NP (NNS inhibitors))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN LY294002))
                      (, ,)
                      (NP (NN PDTC)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (CD 16) (NNS hours))
          (PP (IN of)
            (NP (NN incubation)))))
      (, ,)
      (NP (NN mRNA))
      (VP (VBD was)
        (VP (VBN extracted)
          (PP (IN with)
            (NP
              (NP (NN RNAzol) (NN B))
              (PRN (-LRB- -LRB-)
                (NP (NN Biotex)
                  (NP (NNS Laboratories))
                  (, ,)
                  (NP (NN Houston))
                  (, ,)
                  (NP (NN TX))
                  (, ,)
                  (NP (NN USA)))
                (-RRB- -RRB-))))
          (PP (IN in)
            (NP
              (NP (NN accordance))
              (PP (IN with)
                (NP
                  (NP (DT the) (NN manufacturer) (POS 's))
                  (NNS instructions))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Reverse) (NN transcription))
        (PP (IN of)
          (NP
            (NP (CD 2) (NN μg))
            (PP (IN of)
              (NP (JJ total) (NN mRNA))))))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN at)
            (NP (NN 42°C)))
          (S
            (VP (VBG using)
              (NP
                (NP (DT the) (NN Superscript™) (NN reverse) (NN transcription) (NN system))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NNP Takara))
                    (, ,)
                    (NP (NN Shiga))
                    (, ,)
                    (NP (NNP Japan)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN PCR) (NN amplification))
        (PP (IN of)
          (NP (NN cDNA) (NNS aliquots))))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN by)
            (S
              (VP (VBG adding)
                (NP
                  (NP
                    (ADJP (CD 2.5) (NN mM))
                    (NN dNTPs))
                  (, ,)
                  (NP
                    (NP (CD 2.5) (NN U))
                    (PP (IN of)
                      (NP
                        (NP (NN Taq) (NN DNA) (NN polymerase))
                        (PRN (-LRB- -LRB-)
                          (NP (NN Takara))
                          (-RRB- -RRB-)))))
                  (CC and)
                  (NP
                    (NP (CD 0.25) (NN μM))
                    (PP (IN of)
                      (NP
                        (NP (NN sense))
                        (CC and)
                        (NP (JJ antisense) (NNS primers))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN reaction))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN in)
            (NP
              (NP (NN PCR) (NN buffer))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP
                    (ADJP (CD 1.5) (NN mM))
                    (NN MgCl2))
                  (, ,)
                  (NP
                    (ADJP (CD 50) (NN mM))
                    (NN KCl))
                  (, ,)
                  (NP
                    (ADJP (CD 10) (NN mM))
                    (NN Tris-HCl)))
                (, ,)
                (NP (NN pH) (CD 8.3))
                (-RRB- -RRB-))))
          (PP (IN in)
            (NP
              (NP (DT a) (JJ total) (NN volume))
              (PP (IN of)
                (NP (CD 25) (NN μl))))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (VBG following) (NN sense)
        (CC and)
        (JJ antisense) (NNS primers))
      (PP (IN for)
        (NP (DT each) (NNS molecules))))
    (VP (VBD were)
      (VP (VBN used) (: :)
        (NP
          (NP (NN IL-17) (NN sense))
          (, ,)
          (NP
            (NP (NN 5'-ATG))
            (VP (VB ACT)
              (NP (NN CCT) (NN GGG) (NN AAG) (NN ACC) (NN TCA) (NN TTG-3) (POS '))))
          (: ;)
          (NP
            (NP (NN IL-17) (NN antisense))
            (, ,)
            (NP (NN 5'-TTA) (NN GGC) (NN CAC) (NN ATG) (NN GTG) (NN GAC) (NN AAT) (NN CGG-3) ('' ')))
          (: ;)
          (NP
            (NP (NN glyceraldehyde-3-phosphate) (NN dehydrogenase))
            (PRN (-LRB- -LRB-)
              (NP (NN GAPDH))
              (-RRB- -RRB-))
            (NP (NN sense))
            (, ,)
            (NP (NN 5'-CGA) (NN TGC) (NN TGG) (NN GCG) (NN TGA) (NN GTA) (NN C-3))
            ('' '))
          (: ;)
          (NP (NN GAPDH) (NN antisense))
          (, ,)
          (NP (NN 5'-CGT) (NN TCA) (NN GCT) (NN CAG) (NN GGA) (NN TGA) (NN CC-3))
          ('' '))))
    (. .)))

(
  (S
    (NP (NNS Reactions))
    (VP (VBD were)
      (VP (VBN processed)
        (PP (IN in)
          (NP (DT a) (NN DNA) (JJ thermal) (NN cycler)))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (NNP Perkin-Elmer) (NNP Cetus) (, ,) (NNP Norwalk))
            (, ,)
            (NP (NN CT))
            (, ,)
            (NP (NNP USA)))
          (-RRB- -RRB-))
        (PP (IN through)
          (NP
            (NP (NNS cycles))
            (PP (IN for)
              (NP
                (NP (CD 30) (NNS s))
                (PP (IN of)
                  (NP
                    (NP (NN denaturation))
                    (PP (IN at)
                      (NP
                        (NP (NN 94°C))
                        (, ,)
                        (NP
                          (NP (CD 1) (NN min))
                          (PP (IN of)
                            (NP (NN annealing))))))
                    (PP (IN at)
                      (NP
                        (NP (NN 56°C))
                        (PP (IN for)
                          (NP
                            (NP (NN GAPDH))
                            (CC and)
                            (NP (NN IL-17))))))
                    (, ,)
                    (VP (VBN followed)
                      (PP (IN by)
                        (NP
                          (NP (CD 1) (NN min))
                          (PP (IN of)
                            (NP
                              (NP (NN elongation))
                              (PP (IN at)
                                (NP (NN 72°C))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN PCR) (NNS rounds))
      (VP (VBD were)
        (VP (VBN repeated)
          (PP (IN for)
            (NP
              (NP
                (NP (CD 25) (NNS cycles))
                (NP (DT each)))
              (PP (IN for)
                (NP (CC both)
                  (NP (NN GAPDH))
                  (CC and)
                  (NP (NN IL-17)))))))))
    (: ;)
    (S
      (NP (DT this))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN as)
            (S
              (VP (VBG falling)
                (PP (IN within)
                  (NP
                    (NP (DT the) (JJ exponential) (NN phase))
                    (PP (IN of)
                      (NP (NN amplification)))
                    (PP (IN for)
                      (NP (DT each) (NN molecule)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN level))
        (PP (IN of)
          (NP (NN mRNA) (NN expression))))
      (VP (VBD was)
        (VP (VBN presented)
          (PP (IN as)
            (NP
              (NP (DT a) (NN ratio))
              (PP (IN of)
                (NP (NN IL-17) (NN PCR) (NN product)))
              (PP (IN over)
                (NP (NN GAPDH) (NN product))))))))
    (. .)))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN with)
            (NP
              (NP (NN anti-CD3))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN μg/ml))
                (-RRB- -RRB-))))
          (PP (IN in)
            (NP
              (NP (DT the)
                (NP (NN presence))
                (CC or)
                (NP (NN absence)))
              (PP (IN of)
                (NP (NN LY294002)))))
          (PRN (-LRB- -LRB-)
            (NP (CD 20) (NN μM))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN incubation))
          (PP (IN for)
            (NP (CD 1) (NN hour)))))
      (, ,)
      (NP (JJ whole) (NN cell) (NNS lysates))
      (VP (VBD were)
        (VP
          (VP (VBN prepared)
            (PP (IN from)
              (NP
                (QP (RB about) (CD 107))
                (NNS cells)))
            (PP (IN by)
              (NP
                (NP (NN homogenization))
                (PP (IN in)
                  (NP (DT the) (NN lysis) (NN buffer))))))
          (, ,)
          (CC and)
          (VP (VBN centrifuged)
            (PP (IN at)
              (NP
                (NP (CD 14,000) (NN r.p.m.))
                (PRN (-LRB- -LRB-)
                  (NP (CD 19,000) (NN g))
                  (-RRB- -RRB-))))
            (PP (IN for)
              (NP (CD 15) (NN min)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Protein) (NNS concentrations))
        (PP (IN in)
          (NP (DT the) (NNS supernatants))))
      (VP (VBD were)
        (VP (VBN determined)
          (PP (IN with)
            (NP (DT the) (NN Bradford) (NN method)))
          (PRN (-LRB- -LRB-)
            (NP (JJ Bio-Rad))
            (, ,)
            (NP
              (NP (NNP Hercules))
              (, ,)
              (NP (NN CA))
              (, ,)
              (NP (NNP USA)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP (NN Protein) (NNS samples))
      (VP (VBD were)
        (VP
          (VP
            (VP (VBN separated)
              (PP (IN by)
                (NP
                  (ADJP (CD 10) (NN %))
                  (NN SDS–PAGE))))
            (CC and)
            (VP (VBN transferred)
              (PP (TO to)
                (NP (DT a) (NN nitrocellulose) (NN membrane)))))
          (PRN (-LRB- -LRB-)
            (NP (NNP Amersham) (NNP Pharmacia) (NNP Biotech) (, ,) (NNP Uppsala) (, ,) (NNP Sweden))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (NP (NN western) (NN hybridization)))
      (, ,)
      (NP (NN membrane))
      (VP (VBD was)
        (VP (VBN preincubated)
          (PP (IN with)
            (NP
              (ADJP (CD 0.1) (NN %))
              (JJ skimmed) (NN milk)))
          (PP (IN in)
            (NP
              (NP
                (NP (JJ TBS-T) (NN buffer))
                (PRN (-LRB- -LRB-)
                  (NP (CD 0.1) (NN %)
                    (NP
                      (NP (NNP Tween) (CD 20))
                      (PP (IN in)
                        (NP (JJ Tris-buffered) (NN saline)))))
                  (-RRB- -RRB-)))
              (PP (IN at)
                (NP (JJ room) (NN temperature)))))
          (PP (IN for)
            (NP (CD 2) (NNS hours))))))
    (, ,)
    (NP
      (NP (RB then) (JJ primary) (NNS antibodies))
      (PP (IN against)
        (NP
          (NP (NN Akt))
          (, ,)
          (NP
            (NP
              (NP (JJ phosphorylated) (NN Akt))
              (CC and)
              (NP (NN IκB-α)))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN Cell) (NN Signaling) (NN Technology))
                (NP (NNP Inc.) (, ,) (NNP Beverly) (, ,) (NNP MA) (, ,) (NNP USA)))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (JJ diluted) (NN 1:1000))
            (PP (IN in)
              (NP
                (ADJP (CD 5) (NN %))
                (NN BSA/TBS-T))))
          (, ,))))
    (VP (VBD were)
      (VP
        (VP (VBN added))
        (CC and)
        (VP (VBN incubated)
          (S
            (ADJP (JJ overnight)
              (PP (IN at)
                (NP (NN 4°C))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (S
          (VP (VBG washing)
            (NP (CD four) (NNS times))
            (PP (IN with)
              (NP (NN TBS-T))))))
      (, ,)
      (NP (NN horseradish) (JJ peroxidase-conjugated) (JJ secondary) (NNS antibodies))
      (VP (VBD were)
        (VP
          (VP (VBN added))
          (CC and)
          (VP (VBN allowed)
            (PP (TO to)
              (NP (NN incubate)))
            (PP (IN for)
              (NP (CD 1) (NN hour)))
            (PP (IN at)
              (NP (JJ room) (NN temperature)))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (JJ TBS-T) (VBG washing)))
      (, ,)
      (NP (VBN hybridized) (NNS bands))
      (VP (VBD were)
        (VP (VBN detected)
          (PP (IN with)
            (NP
              (NP (DT the) (VBN enhanced) (NN chemiluminescence) (-LRB- -LRB-) (NN ECL) (-RRB- -RRB-) (NN detection) (NN kit))
              (CC and)
              (NP
                (NP (NN Hyperfilm-ECL) (NNS reagents))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Amersham) (NNP Pharmacia))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Nuclear) (NNS proteins))
      (VP (VBD were)
        (VP (VBN extracted)
          (PP (IN from)
            (NP
              (QP (RB about) (CD 5))
              (NN ×) (CD 106) (NN PBMC))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Oligonucleotide) (NNS probes))
      (VP (VBG encompassing)
        (NP
          (NP (DT the) (JJ NF-κB) (NN binding) (NN site))
          (PP (IN of)
            (NP (DT the)
              (NP
                (NP (JJ human) (NN IL-17) (NN promoter))
                (PRN (-LRB- -LRB-)
                  (NP (NN 5'-ATG) (NN ACC) (NN TGG) (NN AAA) (NN TAC) (NN CCA) (NN AAA) (NN TTC-3) ('' '))
                  (-RRB- -RRB-))))))))
    (VP (VBD were)
      (VP (VBN generated)
        (PP (IN by)
          (NP
            (NP (JJ 5'-end) (NN labeling))
            (PP (IN of)
              (NP (DT the) (NN sense) (NN strand)))
            (PP (IN with)
              (NP
                (NP
                  (NP (CD -LSB-γ-32P) (-RRB- -RSB-) (NN dATP))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP Amersham) (NNP Pharmacia))
                    (-RRB- -RRB-)))
                (CC and)
                (NP
                  (NP (NN T4) (NN polynucleotide) (NN kinase))
                  (PRN (-LRB- -LRB-)
                    (NP (NN TaKaRa))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Unincorporated) (NNS nucleotides))
      (VP (VBD were)
        (VP (VBN removed)
          (PP (IN by)
            (NP
              (NP (NN NucTrap) (NN probe) (NN purification) (NNS columns))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NNP Stratagene))
                  (, ,)
                  (NP (NN La) (NN Jolla))
                  (, ,)
                  (NP (NN CA) (, ,) (NNP USA)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Nuclear) (NNS extracts))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (CD 2) (NN μg))
            (PP (IN of)
              (NP (NN protein))))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN with)
            (NP
              (NP (VBN radiolabeled) (NN DNA) (NNS probes))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN ng) (: ;) (CD 100,000) (NN c.p.m.))
                (-RRB- -RRB-))))
          (PP (IN for)
            (NP
              (NP (CD 30) (NN min))
              (PP (IN at)
                (NP
                  (NP (JJ room) (NN temperature))
                  (PP (IN in)
                    (NP
                      (NP (CD 20) (NN μl))
                      (PP (IN of)
                        (NP
                          (NP (NN binding) (NN buffer))
                          (VP (VBG consisting)
                            (PP (IN of)
                              (NP
                                (NP
                                  (ADJP (CD 20) (NN mM))
                                  (NN Tris-HCl))
                                (, ,)
                                (NP (NN pH) (CD 7.9))
                                (, ,)
                                (NP (CD 50) (NN mM) (NN KCl))
                                (, ,)
                                (NP (CD 1) (NN mM) (NN dithiothreitol))
                                (, ,)
                                (NP
                                  (ADJP (CD 0.5) (NN mM))
                                  (NN EDTA))
                                (, ,)
                                (NP
                                  (ADJP (CD 5) (NN %))
                                  (NN glycerol))
                                (, ,)
                                (NP (CD 1) (NN mg/ml) (NN BSA))
                                (, ,)
                                (NP
                                  (ADJP (CD 0.2) (NN %))
                                  (NN Nonidet) (NN P40))
                                (CC and)
                                (NP
                                  (NP
                                    (ADJP (CD 50) (NN ng/μl))
                                    (NN poly))
                                  (PRN (-LRB- -LRB-)
                                    (NP (NN dI-dC))
                                    (-RRB- -RRB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Samples))
      (VP (VBD were)
        (VP (VBN subjected)
          (PP (TO to)
            (NP (NN electrophoresis)))
          (PP (IN on)
            (NP
              (NP (JJ nondenaturing)
                (ADJP (CD 5) (NN %))
                (NN polyacrylamide) (NNS gels))
              (PP (IN in)
                (NP
                  (NP
                    (NP
                      (ADJP (CD 0.5) (NN ×))
                      (NN Tris-borate-EDTA) (NN buffer))
                    (PRN (-LRB- -LRB-)
                      (NP (NN pH) (CD 8.0))
                      (-RRB- -RRB-)))
                  (PP (IN at)
                    (NP
                      (ADJP (CD 100) (NN V.))
                      (NNS Gels))))))))))
    (VP (VBD were)
      (VP
        (VP (VBN dried)
          (PP (IN under)
            (NP (NN vacuum))))
        (CC and)
        (VP (VBN exposed)
          (PP (TO to)
            (NP
              (NP (NN Kodak) (NN X-OMAT) (NN film))
              (PP (IN at)
                (NP
                  (NP (NN -70°C))
                  (PP (IN with)
                    (NP (JJ intensifying) (NNS screens))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Rabbit) (JJ polyclonal) (NNS antibodies))
        (PP (IN against)
          (NP (NN NF-κB) (NNS subunits)
            (NP
              (NP (NN p50))
              (, ,)
              (NP (NN p65))
              (CC and)
              (NP (NN c-Rel))))))
      (VP (VBD were)
        (PP (IN from)
          (NP (NNP Santa) (NNP Cruz) (NN Biotechnology)))
        (PRN (-LRB- -LRB-)
          (NP (NNP Santa) (NNP Cruz))
          (, ,)
          (NP
            (NP (NN CA))
            (, ,)
            (NP (NN USA)))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (NP (NN cell) (NN viability) (NNS assays)))
      (, ,)
      (NP (DT the)
        (NP (NN trypan) (JJ blue) (NN dye) (NN exclusion))
        (NN method))
      (VP (VBD was)
        (VP (VBN used)
          (S
            (VP (TO to)
              (VP (VB evaluate)
                (NP
                  (NP (DT the) (NN potential))
                  (PP (IN of)
                    (NP
                      (NP (JJ direct) (JJ cytotoxic) (NN effect))
                      (PP (IN of)
                        (NP (NNS inhibitors)))
                      (PP (IN on)
                        (NP (NNS cells))))))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (NN incubation))
        (PP (IN for)
          (NP (CD 24) (NNS hours)))))
    (, ,)
    (S
      (S
        (NP (DT the) (NNS cells))
        (VP (VBD were)
          (VP (VBN harvested))))
      (CC and)
      (S
        (NP (DT the) (NN percentage) (NN cell) (NN viability))
        (VP (VBD was)
          (VP (VBN calculated)
            (PP (IN with)
              (NP
                (NP (DT the) (NN formula) (CD 100) (NN ×))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN number))
                    (PP (IN of)
                      (NP
                        (NP (JJ viable) (NN cells/number))
                        (PP (IN of)
                          (NP
                            (ADJP (CC both)
                              (ADJP (JJ viable))
                              (CC and)
                              (ADJP (JJ dead)))
                            (NNS cells))))))
                  (-RRB- -RRB-)
                  (NP (NN -LSB-21))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Data))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (NNS means))
              (VP (VBG ±)
                (NP (NN SEM))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Statistical) (NN analysis))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN with)
            (NP
              (NP
                (NP (NN Student) (POS 's))
                (NN t-test))
              (PP (IN for)
                (NP (VBN matched) (NNS pairs))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN P) (NNS values))
        (ADJP (JJR less)
          (PP (IN than)
            (NP (CD 0.05)))))
      (VP (VBD were)
        (VP (VBN considered)
          (ADJP (JJ significant)))))
    (. .)))

(
  (S
    (NP (NNS Results))))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBD were)
        (VP
          (VP (VBN separated))
          (CC and)
          (VP (VBN cultured)
            (PP (IN with)
              (NP
                (NP (NN PHA))
                (PRN (-LRB- -LRB-)
                  (NP (CD 5) (NN μg/ml))
                  (-RRB- -RRB-))))
            (PP (IN from)
              (NP
                (NP
                  (NP (NNS patients))
                  (PP (IN with)
                    (NP (NN RA))))
                (, ,)
                (NP
                  (NP (NNS patients))
                  (PP (IN with)
                    (NP (NN OA))))
                (, ,)
                (CC and)
                (NP (JJ age-matched) (JJ normal) (NNS controls))))))))
    (: ;)
    (S
      (NP (NN IL-17) (NNS levels))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN determined)
          (PP (IN in)
            (NP
              (NP (DT the) (NN culture) (NNS supernatants))
              (PRN (-LRB- -LRB-)
                (NP (NNP Fig.) (CD 1))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (SBAR (IN Although)
      (S
        (NP
          (NP (DT the) (NNS amounts))
          (PP (IN of)
            (NP (JJ basal) (NN IL-17) (NN secretion))))
        (VP (VBD were) (RB not)
          (ADJP (JJ different)
            (PP (IN between)
              (NP
                (NP (NN RA))
                (, ,)
                (NP (NN OA))
                (CC and)
                (NP
                  (NP (JJ normal) (NNS controls))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (CD 62) (NN ±) (CD 31))
                      (, ,)
                      (NP (CD 43) (NN ±) (CD 19)
                        (CC and)
                        (CD 43) (NN ±) (CD 10) (NN pg/ml))
                      (, ,)
                      (ADVP (RB respectively)))
                    (-RRB- -RRB-)))))))))
    (, ,)
    (NP
      (NP (DT the) (NN IL-17) (NN production))
      (VP (VBN stimulated)
        (PP (IN by)
          (NP (NN PHA)))))
    (VP (VBD was)
      (ADJP
        (ADJP (RB significantly) (JJR higher))
        (PP (IN in)
          (NP (NN RA) (NNS PBMC)))
        (PP (IN than)
          (PP (IN in)
            (NP
              (NP (DT those))
              (PP (IN from)
                (NP
                  (NP
                    (NP
                      (NP (NNS OA))
                      (CC and)
                      (NP (NNS controls)))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 768) (NN ±) (CD 295)
                        (CC versus)
                        (CD 463) (NN ±) (CD 211) (NN pg/ml) (NN -LSB-P) (NN <) (CD 0.05))
                      (-RRB- -RSB-)))
                  (CC and)
                  (NP
                    (NP (NN 241) (NN ±) (CD 29) (NN pg/ml) (NN -LSB-P))
                    (PRN
                      (QP (RB <) (CD 0.001))
                      (-RRB- -RSB-) (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (SBAR (IN Because)
      (S
        (NP (NN IL-17))
        (VP (VBD was)
          (ADVP (RB already))
          (VP (VBN known)
            (PP (IN from)
              (NP (JJR earlier) (NNS reports))))
          (S
            (VP (TO to)
              (VP (VB be)
                (VP (VBN produced)
                  (ADVP (RB mainly))
                  (PP (IN by)
                    (NP (VBN activated) (NN T) (NNS cells))))))))))
    (, ,)
    (NP (PRP we))
    (VP (VBD investigated)
      (NP
        (NP (DT the) (NN effect))
        (PP (IN of)
          (NP
            (NP (JJ different) (NNS concentrations))
            (PP (IN of)
              (NP
                (NP (NN anti-CD3))
                (PRN (-LRB- -LRB-)
                  (NP
                    (QP (CD 1) (, ,) (CD 5)
                      (CC and)
                      (CD 10))
                    (NN μg/ml))
                  (-RRB- -RRB-)))))))
      (PP (IN as)
        (NP
          (NP (DT a) (NN T) (NN cell) (NN activation))
          (, ,)
          (SBAR
            (WHNP (WDT which))
            (S
              (VP (VBD showed)
                (NP
                  (NP (DT a) (JJ dose-dependent) (NN increase))
                  (PP (IN in)
                    (NP (NN IL-17) (NNS levels))))
                (PRN (-LRB- -LRB-)
                  (S
                    (NP (NNS data))
                    (VP (RB not) (VBN shown)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (PP (IN On) (DT the) (NN basis) (IN of)
      (NP (DT this)))
    (, ,)
    (NP (PRP we))
    (VP (VBP chose)
      (NP (CD 10) (NN μg/ml))
      (PP (IN as)
        (NP
          (NP (DT a) (NN stimulation) (NN concentration))
          (PP (IN for)
            (NP (NN anti-CD3))))))
    (. .)))

(
  (S
    (SBAR (IN As)
      (S
        (VP (VBN shown)
          (PP (IN in)
            (NP (NN Table) (CD 1))))))
    (, ,)
    (S
      (S
        (NP (NN anti-CD3))
        (ADVP (RB significantly))
        (VP (VBD upregulated)
          (NP
            (NP (NN IL-17) (NN production))
            (ADJP (CD up) (TO to) (JJ 3.7-fold)))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT the) (NN combination))
          (PP (IN of)
            (NP
              (NP (NN anti-CD28))
              (CC and)
              (NP (NN anti-CD3)))))
        (VP (VBD produced)
          (NP (JJR more) (NN IL-17))
          (PRN (-LRB- -LRB-)
            (NP (RB approximately) (RB 1.3-1.5-fold))
            (-RRB- -RRB-)))))))

(
  (S
    (PP (IN than)
      (NP
        (NP (NN anti-CD3))
        (ADVP (RB alone))))
    (. .)))

(
  (S
    (ADVP (RB Furthermore))
    (, ,)
    (SBAR
      (WHADVP (WRB when))
      (S
        (VP (VBN incubated)
          (PP (IN with)
            (NP
              (NP (NN T) (NN cell) (NNS mitogens))
              (PP (JJ such) (IN as)
                (NP (NN PHA))))))))
    (, ,)
    (NP (VBN increased) (NN IL-17) (NN production))
    (VP (VBD was)
      (ADJP (RBR more) (JJ pronounced))
      (PP (IN than)
        (PP (IN with)
          (NP
            (NP
              (ADJP (JJ anti-CD3)))
            (CC and)
            (NP
              (ADJP (JJ anti-CD28))))))
      (PRN (-LRB- -LRB-)
        (NP
          (NP (NN 588) (NN ±) (CD 85)
            (CC versus)
            (CD 211) (NN ±) (CD 1) (NN pg/ml))
          (: ;)
          (NP (NN P) (NN <) (CD 0.05)))
        (-RRB- -RRB-)))
    (. .)))

(
  (S
    (SBAR (IN Because)
      (S
        (NP (NN RA) (NNS PBMC))
        (VP (VBP include)
          (NP
            (NP (JJ several) (NN cell) (NNS types))
            (PP (IN in) (NN addition) (TO to)
              (NP (NN T) (NNS cells)))))))
    (, ,)
    (NP
      (NP (DT some) (JJ inflammatory) (NNS cytokines))
      (VP (VBN released)
        (PP (IN from)
          (NP
            (NP (NNS macrophages))
            (CC and)
            (NP (JJ other) (NNS lymphocytes))))))
    (VP (MD might)
      (VP (VB have)
        (VP (VBD affected)
          (NP
            (NP (DT the) (NN production))
            (PP (IN of)
              (NP (NN IL-17)))
            (PP (IN from)
              (NP (NN T) (NNS cells)))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB evaluate)
            (NP
              (NP (DT the) (NNS effects))
              (PP (IN of)
                (NP
                  (NP (JJ inflammatory) (NNS cytokines))
                  (VP (VBN released)
                    (PP (IN by)
                      (NP (VBN activated) (NNS PBMC))))))))))
      (, ,)
      (NP (PRP we))
      (VP (VBD tested)
        (NP
          (NP (DT the) (NNS effects))
          (PP (IN of)
            (NP
              (NP (JJ several) (NNS cytokines))
              (CC and)
              (NP (NNS chemokines))))
          (PP (IN on)
            (NP (NN IL-17) (NN production))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (PRP We))
        (VP (VBD detected)
          (NP
            (NP (DT an) (NN increase))
            (PP (IN in)
              (NP (NN IL-17) (NN level))))
          (PP (IN after)
            (NP
              (NP (NN stimulation))
              (PP (IN with)
                (NP
                  (NP (NN IL-15))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 10) (NN ng/ml))
                    (-RRB- -RRB-))))))))
      (, ,) (IN whereas)
      (S
        (PP (IN with)
          (NP
            (NP
              (NP (NN IL-1β))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN ng/ml))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (NN TNF-α))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN ng/ml))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (NN IL-18))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN ng/ml))
                (-RRB- -RRB-)))
            (CC or)
            (NP
              (NP (NN TGF-β))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN ng/ml))
                (-RRB- -RRB-)))))
        (NP
          (NP (DT the) (NNS levels))
          (PP (IN in)
            (NP (NN IL-17))))
        (VP (VBD were)
          (ADJP
            (ADJP (JJ unchanged))
            (PRN (-LRB- -LRB-)
              (NP (NNP Fig.) (NN 2a))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (SBAR
      (WHADVP (WRB When))
      (S
        (VP (VBN treated)
          (PP (IN with)
            (NP
              (NP
                (NP (NN MCP-1))
                (PRN (-LRB- -LRB-)
                  (NP (CD 10) (NN ng/ml))
                  (-RRB- -RRB-)))
              (CC or)
              (NP
                (NP (NN IL-6))
                (PRN (-LRB- -LRB-)
                  (NP (CD 10) (NN ng/ml))
                  (-RRB- -RRB-))))))))
    (, ,)
    (S
      (S
        (NP
          (NP (JJ significant) (NNS upregulations))
          (PP (IN of)
            (NP (NN IL-17) (NNS proteins))))
        (VP (VBD were)
          (VP (VBN observed)
            (PRN (-LRB- -LRB-)
              (S
                (S
                  (NP (CD 62) (NN ±)
                    (QP (CD 42)
                      (CC and)
                      (CD 50)))
                  (VP (JJ ±)
                    (NP
                      (QP (CD 10)
                        (CC versus)
                        (CD 31) (CD ±) (CD 11))
                      (NN pg/ml))
                    (, ,)
                    (ADVP (RB respectively))))
                (: ;)
                (NP (NN P) (JJ <) (CD 0.05)))
              (-RRB- -RRB-)))))
      (, ,) (IN whereas)
      (S
        (NP (NN none))
        (VP (VBD was)
          (VP (VBN observed)
            (PP (IN with)
              (NP
                (NP
                  (NP (NN IL-8))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 10) (NN ng/ml))
                    (-RRB- -RRB-)))
                (, ,)
                (NP
                  (NP (NN MIP-1α))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 10) (NN ng/ml))
                    (-RRB- -RRB-)))
                (CC or)
                (NP
                  (NP
                    (NP (NN MIP-1β))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 10) (NN ng/ml))
                      (-RRB- -RRB-)))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP Fig.) (NN 2b))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (VBG Having)
          (VP (VBN observed)
            (NP
              (NP (DT the) (VBN increased) (NN IL-17) (NN production))
              (PP (IN in)
                (NP (NN RA) (NNS PBMC)))))))
      (, ,)
      (NP (PRP it))
      (VP (VBD was)
        (ADJP (JJ important)
          (S
            (VP (TO to)
              (VP (VB know)
                (SBAR
                  (WHNP (WDT which))
                  (S
                    (NP (NN signal) (NN transduction) (NNS pathways))
                    (VP (VBD were)
                      (VP (VBN involved)))))))))))
    (. .)))

(
  (S
    (SBAR (IN As)
      (S
        (VP (VBN illustrated)
          (PP (IN in)
            (NP (NNP Fig.) (CD 3))))))
    (, ,)
    (NP
      (NP (DT an) (JJ significant) (NN decrease))
      (PP (IN in)
        (NP (JJ anti-CD3-induced) (NN IL-17) (NN production))))
    (VP (VBD was)
      (VP (VBN observed)
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN co-incubated)
              (PP (IN with)
                (NP
                  (NP (NN NF-κB) (NN inhibitor))
                  (, ,)
                  (NP
                    (NP
                      (NP
                        (NP (NN PDTC))
                        (CC and)
                        (NP (NN dexamethasone)))
                      (PP (IN in)
                        (NP
                          (NP (NN comparison))
                          (PP (IN with)
                            (NP
                              (NP (NN anti-CD3))
                              (ADVP (RB alone)))))))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP
                          (NP (CD 38) (NN ±)
                            (QP (CD 5)
                              (CC and)
                              (CD 54)))
                          (JJ ±)
                          (NP
                            (QP (CD 11)
                              (CC versus)
                              (CD 98))
                            (NN ±))
                          (CD 19) (NN pg/ml))
                        (, ,)
                        (ADVP (RB respectively)))
                      (: ;)
                      (NP (NN P) (NN <) (CD 0.05))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (NP
      (NP
        (NP (NN LY294002))
        (CC and)
        (NP (NN wortmannin)))
      (, ,)
      (NP
        (NP (RB as) (DT an) (NN inhibitor))
        (PP (IN of)
          (NP (NN PI3K))))
      (, ,))
    (ADVP (RB also))
    (ADVP (RB markedly))
    (VP (VBD inhibited)
      (NP
        (NP
          (NP (DT the) (JJ anti-CD3-induced) (NN IL-17) (NN production))
          (PP (IN in)
            (NP
              (NP (NN RA) (NNS PBMC))
              (PRN (-LRB- -LRB-)
                (NP (CD 98) (NN ±)
                  (QP (CD 19)
                    (CC versus)
                    (CD 38) (CD ±))
                  (CD 10) (NN pg/ml) (NN -LSB-P) (NN <) (CD 0.005))
                (-RRB- -RSB-)))))
        (CC and)
        (NP
          (NP (CD 48) (NN ±) (CD 4) (NN pg/ml) (NN -LSB-P))
          (PRN
            (QP (RB <) (CD 0.05))
            (-RRB- -RSB-)))
        (, ,)
        (ADVP (RB respectively))
        (-RRB- -RRB-)))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN calcineurin) (NNS inhibitors))
        (NP
          (NP (NN cyclosporin) (NN A))
          (CC and)
          (NP (NN FK506))))
      (ADVP (RB also))
      (VP (VBD downregulated)
        (NP
          (NP (DT the) (NN IL-17) (NN secretion))
          (CONJP (RB as) (RB well) (IN as))
          (NP
            (NP
              (NP
                (NP (DT the) (JJ mitogen-activated) (NN protein) (NN kinase))
                (PRN (-LRB- -LRB-)
                  (NP (NN MAPK))
                  (-RRB- -RRB-)))
              (NN p38) (NN inhibitor) (NN SB203580))
            (VP (VBD did))))
        (, ,)
        (SBAR (IN whereas)
          (S
            (NP
              (NP (NN rapamycin))
              (CC and)
              (NP (NN PD98059)))
            (VP (VBD had)
              (NP (DT no) (NN effect))
              (PP (IN on)
                (NP
                  (NP (NN IL-17) (NNS levels))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP Fig.) (CD 3))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (VP (TO To)
        (VP (VB evaluate)
          (NP
            (NP (DT the) (NN possibility))
            (PP (IN of)
              (NP
                (NP (JJ non-specific) (NN inhibition))
                (PP (IN by)
                  (NP (DT the) (NN drug)))
                (PP (IN at)
                  (NP (JJ high) (NNS concentrations)))))))))
    (, ,)
    (NP (PRP we))
    (VP (VBD observed)
      (NP
        (NP (DT the) (NN dose) (NN response))
        (PP (IN of)
          (NP
            (NP (NN PDTC))
            (CC and)
            (NP (NN LY294002))))
        (PP (IN for)
          (NP
            (NP (DT the) (NN inhibition))
            (PP (IN of)
              (NP
                (NP (NN IL-17) (NN production))
                (PP (IN in)
                  (NP (NN PBMC)))))))))
    (. .)))

(
  (S
    (S
      (NP (EX There))
      (VP (VBD were)
        (NP
          (NP (JJ dose-dependent) (NNS inhibitions))
          (PP (IN of)
            (NP (NN IL-17) (NN production)))
          (PP (IN with)
            (NP
              (NP (JJ chemical) (NNS inhibitors))
              (PRN (-LRB- -LRB-)
                (NP (NNP Fig.) (NN 4a))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ other) (NNS inhibitors))
        (PP (IN in)
          (NP
            (NP (NN addition))
            (PP (TO to)
              (NP
                (NP (NN PDTC))
                (CC and)
                (NP (NN LY294002)))))))
      (VP (VBD showed)
        (NP
          (NP (DT the) (JJ same) (NN pattern))
          (PP (IN of)
            (NP (NN inhibition))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Cytotoxic) (NNS effects))
        (PP (IN on)
          (NP (NN PBMC)))
        (PP (IN by)
          (NP
            (NP (DT the) (JJ chemical) (NNS inhibitors))
            (PP (IN at)
              (NP (JJ experimental) (NNS concentrations))))))
      (VP (VBD were) (RB not)
        (VP (VBN observed)
          (PRN (-LRB- -LRB-)
            (NP (NNP Fig.) (CD 4b))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB see)
            (SBAR (IN whether)
              (S
                (NP (VBN enhanced) (NN IL-17) (NN production))
                (VP (MD could)
                  (VP (VB be)
                    (VP (VBN regulated)
                      (PP (IN at)
                        (NP (DT a) (JJ transcriptional) (NN level)))))))))))
      (, ,)
      (NP (JJ semi-quantatitive) (JJ reverse) (NN transcription–polymerase) (NN chain) (NN reaction))
      (VP (VBD was)
        (VP (VBN performed))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD observed)
        (NP
          (NP (DT a) (JJ dose-dependent) (NN increase))
          (PP (IN in)
            (NP (NN IL-17) (NN mRNA) (NNS transcripts))))
        (PP (IN after)
          (NP
            (NP (NN stimulation))
            (PP (IN with)
              (NP (NN anti-CD3)))))))
    (: ;)
    (S
      (NP (DT this))
      (VP (VBD was)
        (VP (VBN inhibited)
          (PP
            (PP (IN by)
              (NP (DT the) (NN PI3K) (NN inhibitor) (NN LY294002)))
            (CC and)
            (PP (IN by)
              (NP
                (NP (DT the) (JJ NF-κB) (NN inhibitor) (NN PDTC))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Fig.) (CD 5))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB determine)
            (NP
              (NP (JJ downstream) (NN effector) (NNS molecules))
              (PP (IN of)
                (NP (DT the) (NN PI3K) (NN pathway)))))))
      (, ,)
      (NP (PRP we))
      (VP (VBD evaluated)
        (NP
          (NP (DT the) (NN activation))
          (PP (IN of)
            (NP (NN Akt)))
          (PP (IN by)
            (NP (NN western) (NN blotting))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN As)
        (S
          (VP (VBN shown)
            (PP (IN in)
              (NP (NNP Fig.) (CD 6)))
            (, ,)
            (PP (IN at)
              (NP
                (NP (CD 10) (NN min))
                (PP (IN of)
                  (NP
                    (NP (NN incubation))
                    (PP (IN with)
                      (NP
                        (NP
                          (NP (NN anti-CD3))
                          (PRN (-LRB- -LRB-)
                            (NP (CD 10) (NN μg/ml))
                            (-RRB- -RRB-)))
                        (CC or)
                        (NP
                          (NP (NN LY294002))
                          (PRN (-LRB- -LRB-)
                            (NP (CD 20) (NN μM))
                            (-RRB- -RRB-))))))))))))
      (, ,)
      (NP
        (NP (DT no) (NN difference))
        (PP (IN in)
          (NP
            (NP (DT the) (NNS amounts))
            (PP (IN of)
              (NP (JJ phosphorylated) (NN Akt))))))
      (VP (VBD was)
        (VP (VBN observed))))
    (. .)))

(
  (S
    (ADVP (RB However))
    (, ,)
    (PP (IN after)
      (NP
        (NP (CD 30) (NN min))
        (PP (IN of)
          (NP (NN incubation)))))
    (, ,)
    (S
      (S
        (NP (VBN phosphorylated) (NN Akt))
        (VP
          (VP (VBD increased))
          (PRN (-LRB- -LRB-)
            (NP (NNP lane) (CD 2))
            (-RRB- -RRB-))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT the) (NN effect))
          (PP (IN of)
            (NP (NN inhibition)))
          (PP (IN by)
            (NP
              (NP (NN LY294002))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 3))
                (-RRB- -RRB-)))))
        (VP (VBD reached)
          (NP (DT a) (NN peak))
          (PP (IN at)
            (NP (CD 60) (NN min)))
          (, ,)
          (S
            (VP (VBG lasting)
              (PP (TO to)
                (NP (CD 120–240) (NN min))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP (JJ non-phosphorylated)
        (NP
          (NP (NN Akt))
          (CC and)
          (NP (NN β-actin))))
      (VP (VBD remained)
        (ADJP (JJ unchanged)
          (ADVP (RB regardless)
            (PP (IN of)
              (NP (NN incubation) (NN time)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN PHA))
        (, ,)
        (NP (NN concanavalin) (NN A))
        (CC and)
        (NP (NN IL-15)))
      (ADVP (RB also))
      (VP (VBD demonstrated)
        (NP
          (NP (DT the) (JJ same) (NN effect))
          (PP (IN on)
            (NP (JJ phosphorylated) (NN Akt))))
        (SBAR (IN as)
          (S
            (VP (VBN shown)
              (PP (IN with)
                (NP
                  (NP (NN anti-CD3))
                  (, ,)
                  (SBAR
                    (WHNP (WDT which))
                    (S
                      (VP (VBD was)
                        (NP
                          (NP (DT an) (NN inhibition))
                          (PP (IN by)
                            (NP
                              (NP (NN wortmannin))
                              (CC and)
                              (NP (NN PDTC))))
                          (PP
                            (CONJP (RB as) (RB well) (IN as))
                            (PP (IN by)
                              (NP (NN LY294002)))))
                        (PRN (-LRB- -LRB-)
                          (S
                            (NP (NNS data))
                            (VP (RB not) (VBN shown)))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (VP (TO To)
        (VP (VB investigate)
          (ADVP (RB further))
          (NP
            (NP (DT the) (JJ intracellular) (NN signaling) (NN pathway))
            (VP (VBN activated)
              (PP (IN by)
                (NP
                  (NP
                    (NP (NN anti-CD3))
                    (CC plus)
                    (NP (NN anti-CD28)))
                  (, ,)
                  (NP (NN concanavalin) (NN A))
                  (, ,)
                  (NP (NN PHA))
                  (CC and)
                  (NP (NN IL-15)))))))))
    (, ,)
    (CC and)
    (S
      (ADJP (JJ responsible)
        (PP (IN for)
          (S
            (VP (VBG inducing)
              (NP (NN IL-17) (NN expression))))))
      (, ,)
      (NP (PRP we))
      (VP (VBD performed)
        (NP
          (NP
            (NP (DT an) (JJ electrophoretic) (NN mobility-shift) (NN assay))
            (PRN (-LRB- -LRB-)
              (NP (NN EMSA))
              (-RRB- -RRB-)))
          (PP (IN of)
            (NP (JJ NF-κB) (NN recognition) (NNS sites))))
        (PP (IN in)
          (NP
            (NP (DT the) (NNS promoters))
            (PP (IN of)
              (NP (NN IL-17)))))))
    (. .)))

(
  (S
    (SBAR (IN As)
      (S
        (VP (VBN shown)
          (PP (IN in)
            (NP (NNP Fig.) (NN 7a))))))
    (, ,)
    (NP
      (NP (JJ nuclear) (NNS extracts))
      (PP (IN from)
        (NP
          (NP (NN RA) (NN PBMC))
          (VP (VBN stimulated)
            (PP (IN with)
              (NP
                (NP (NN anti-CD3))
                (CC plus)
                (NP (NN anti-CD28))))))))
    (PRN (-LRB- -LRB-)
      (NP (NNP lane) (CD 2))
      (-RRB- -RRB-))
    (VP (VBD demonstrated)
      (NP
        (NP (VBN increased) (NN binding))
        (PP (IN of)
          (NP (NN NF-κB)))
        (PP (TO to)
          (NP (NN IL-17) (NNS promoters))))
      (PP (IN in)
        (NP
          (NP (NN comparison))
          (PP (IN with)
            (NP
              (NP (DT that))
              (PP (IN of)
                (NP (NNS controls)))))))
      (PRN (-LRB- -LRB-)
        (NP (NNP lane) (CD 1))
        (-RRB- -RRB-)))
    (. .)))

(
  (S
    (S
      (NP (DT A) (NN supershift) (NN assay))
      (VP (VBD demonstrated)
        (NP
          (NP (VBN shifted) (NNS bands))
          (PP (IN in)
            (NP
              (NP
                (NP
                  (NP (NN p65))
                  (CC and)
                  (NP (NN p50)))
                (PRN (-LRB- -LRB-)
                  (NP (NNS lanes)
                    (QP (CD 3)
                      (CC and)
                      (CD 4)))
                  (-RRB- -RRB-)))
              (CONJP (RB not) (IN in))
              (NP
                (NP (NN c-Rel))
                (PRN (-LRB- -LRB-)
                  (NP (NNP lane) (CD 5))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (S
        (PP (IN In)
          (NP (JJ normal) (NN PBMC)))
        (NP (DT the) (JJ same) (NN pattern))
        (VP (VBD was)
          (VP (VBN observed))))
      (, ,)
      (CC but)
      (S
        (NP
          (NP (DT the) (NN degree))
          (PP (IN of)
            (NP
              (NP (JJ NF-κB) (NN activation))
              (PP (IN by)
                (NP
                  (NP (NN anti-CD3))
                  (CC plus)
                  (NP (NN anti-CD28)))))))
        (VP (VBD was)
          (ADJP (RBR less) (JJ intense)
            (PP (IN than)
              (NP
                (NP (DT that))
                (PP (IN in)
                  (NP
                    (NP (NN RA) (NNS PBMC))
                    (PRN (-LRB- -LRB-)
                      (NP (NNP Fig.) (CD 7b))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB confirm)
            (NP
              (NP (DT the) (NN link))
              (PP (IN between)
                (NP
                  (NP (NN PI3K) (NN activity))
                  (CC and)
                  (NP (NN NF-κB))))))))
      (, ,)
      (NP (PRP we))
      (VP (VBD performed)
        (NP (NN EMSA))
        (S
          (VP (TO to)
            (VP (VB determine)
              (NP (DT the) (JJ NF-κB) (NN binding) (NN activity))
              (PP (IN after)
                (NP
                  (NP (NN treatment))
                  (PP (IN with)
                    (NP (CC both)
                      (NP (NN LY294002))
                      (CC and)
                      (NP (NN PDTC)))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT Both) (NNS agents))
      (VP (VBP block)
        (NP
          (NP (JJ NF-κB) (JJ DNA-binding) (NN activity))
          (PP (IN in)
            (NP (DT the) (NN IL-17) (NN promoter))))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (NNP Fig.))
            (NP (NN 7c)))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Western) (NN blotting))
        (PP (IN for)
          (NP (NN IκB-α))))
      (VP (VBD showed)
        (NP
          (NP (NN inhibition))
          (PP (IN of)
            (NP
              (NP (NN degradation))
              (PP (IN of)
                (NP (NN IκB-α)))))
          (PP (IN by)
            (NP
              (NP (NN LY294002))
              (CC and)
              (NP (NN PDTC)))))
        (PP (IN at)
          (NP
            (NP (DT the) (JJ same) (NN time))
            (PRN (-LRB- -LRB-)
              (NP (NNP Fig.) (NN 7c))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP (DT the) (NN AP-1) (NN pathway))
      (VP (VBD was) (RB not)
        (VP (VBN activated)
          (PP (IN by)
            (NP
              (NP (NN stimulation))
              (PP (IN with)
                (NP
                  (NP (NN anti-CD3))
                  (CC plus)
                  (NP (NN anti-CD28))))))
          (PRN (-LRB- -LRB-)
            (S
              (NP (NNS data))
              (VP (RB not) (VBN shown)))
            (-RRB- -RRB-)))
        (, ,)
        (S
          (VP (VBG demonstrating)
            (SBAR (IN that)
              (S
                (NP (NN NF-κB))
                (VP (VBZ is)
                  (NP
                    (NP (DT the) (JJ main) (JJ intracellular) (NN signaling) (NN pathway))
                    (PP (IN in)
                      (NP
                        (NP (NN IL-17) (NN production))
                        (PP (IN by)
                          (NP
                            (NP (VBN activated) (NN PBMC))
                            (PP (IN from)
                              (NP
                                (NP (NNS patients))
                                (PP (IN with)
                                  (NP (NN RA)))))))))))))))))
    (. .)))

(
  (S
    (NP (NN Discussion))))

(
  (S
    (S
      (NP (NN IL-17))
      (VP (VBD was)
        (ADVP (RB first))
        (VP (VBN described)
          (PP (IN as)
            (NP
              (NP (DT a) (NN T) (NN cell) (NN product))
              (PP (IN with)
                (NP (JJ proinflammatory) (NNS properties) (CD -LSB-5,22) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (NN RA))
      (VP (VBZ is)
        (VP (VBN characterized)
          (PP (IN by)
            (NP
              (NP
                (NP (NN hyperplasia))
                (PP (IN of)
                  (NP (JJ synovial) (NN lining) (NNS cells))))
              (CC and)
              (NP
                (NP (DT an) (JJ intense) (NN infiltration))
                (PP (IN by)
                  (NP (JJ mononuclear) (NNS cells) (CD -LSB-23) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (JJ Proinflammatory) (NNS cytokines))
          (PP (JJ such) (IN as)
            (NP
              (NP (NN IL-1))
              (CC and)
              (NP (NN TNF-α)))))
        (VP (VBP are)
          (ADJP (JJ abundant)
            (PP (IN in)
              (NP (JJ rheumatoid) (NN synovium))))))
      (, ,) (IN whereas)
      (S
        (NP
          (NP (DT the) (NN T) (JJ cell-derived) (NNS cytokines))
          (, ,)
          (ADVP (RB especially))
          (NP
            (NP (NN IL-4))
            (CC and)
            (NP (NN interferon-γ)))
          (, ,))
        (VP (VBP have)
          (ADVP (RB often))
          (S
            (VP (VBD proved)
              (ADJP (JJ difficult)
                (S
                  (VP (TO to)
                    (VP (VB detect)
                      (PP (IN in)
                        (NP (NN RA) (NN synovium) (CD -LSB-24)))))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP (NN T) (NNS cells))
          (VP (MD may)
            (VP (VB have)
              (NP (DT a) (NN role))
              (PP (IN in)
                (NP
                  (NP (DT the) (NN augmentation))
                  (PP (IN of)
                    (NP (JJ rheumatoid) (JJ synovial) (NN inflammation)))))))))
      (, ,)
      (NP
        (NP (DT the) (NN lack))
        (PP (IN of)
          (NP (NN T) (JJ cell-derived) (NNS cytokines))))
      (VP (VBZ has)
        (VP (VBN limited)
          (NP (PRP$ its) (NN importance)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT this) (NN respect)))
      (, ,)
      (NP (NN IL-17))
      (VP (VBZ is)
        (VP (VBG appealing)
          (SBAR (IN because)
            (S
              (NP (PRP it))
              (VP (VBZ has)
                (VP (VBN been)
                  (VP (VBN described)
                    (PP (IN as)
                      (NP
                        (NP (DT a)
                          (ADJP (NN T) (JJ cell-derived))
                          (NN cytokine))
                        (PP (IN with)
                          (NP (JJ proinflammatory) (NNS properties)))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (PRP$ our) (NNS studies)))
      (, ,)
      (NP (PRP we))
      (VP (VBD tried)
        (S
          (VP (TO to)
            (VP (VB evaluate)
              (SBAR
                (SBAR
                  (WHADVP (WRB how))
                  (S
                    (NP (NN IL-17) (NN production))
                    (VP (VBZ is)
                      (VP (VBN regulated)
                        (PP (IN in)
                          (NP (NN RA) (NNS PBMC)))))))
                (, ,)
                (CC and)
                (SBAR
                  (WHNP (WDT which))
                  (S
                    (NP (NN signaling) (NN pathway))
                    (NP (PRP it)
                      (VP (VBN used)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Levels))
        (PP (IN of)
          (NP (NN IL-17))))
      (VP (VBD were)
        (VP (VBN found)
          (S
            (VP (TO to)
              (VP (VB be)
                (ADJP
                  (ADJP (JJR higher))
                  (PP (IN in)
                    (NP (NN RA) (JJ synovial) (NN fluid)))
                  (PP (IN than)
                    (FRAG
                      (PP (IN in)
                        (NP (JJ OA) (JJ synovial) (NN fluid) (CD -LSB-15)))
                      (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP (EX there))
      (VP (VBP are)
        (NP
          (NP (JJ few) (NNS data))
          (ADJP (JJ available)
            (PP (IN on)
              (NP (DT the) (NNS agents))))
          (SBAR
            (WHNP (WDT that))
            (S
              (VP (VBP stimulate)
                (NP
                  (NP (NN IL-17) (NN production))
                  (PP (IN in)
                    (NP (NN RA))))
                (, ,)
                (SBAR (IN although)
                  (S
                    (NP
                      (NP (DT the) (JJS highest) (NN level))
                      (PP (IN of)
                        (NP (NN IL-17) (NN production))))
                    (VP (MD can)
                      (VP (VB be)
                        (VP (VBN achieved)
                          (PP (IN by)
                            (NP
                              (NP (JJ anti-CD3/anti-CD28) (NN stimulation))
                              (PP (IN in)
                                (NP (JJ healthy) (NNS individuals) (CD -LSB-25) (-RRB- -RSB-))))))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (PRP$ our) (NNS experiments)))
      (, ,)
      (NP
        (NP (NN PHA))
        (PP (IN as)
          (NP
            (NP (NNS mitogens))
            (, ,)
            (CONJP (RB as) (RB well) (IN as))
            (NP
              (ADJP (JJ anti-CD3/anti-CD28)
                (PP (IN for)
                  (NP
                    (NP (NN signaling))
                    (PP (IN through)
                      (NP (DT the) (NN T) (NN cell) (NN receptor)))))))
            (, ,))))
      (VP (VBD increased)
        (NP (NN IL-17) (NN production))
        (PP (IN from)
          (NP (NN RA) (NN PBMC)))
        (PP (IN in)
          (NP (DT a) (JJ dose-dependent) (NN manner)))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD found) (, ,)
        (PP (IN by)
          (NP
            (NP (DT a) (NN cell) (NN proliferation) (NN assay))
            (PRN (-LRB- -LRB-)
              (S
                (NP (NNS data))
                (VP (RB not) (VBN shown)))
              (-RRB- -RRB-))))
        (, ,)
        (SBAR (IN that)
          (S
            (NP
              (NP (DT this) (NN upregulation))
              (PP (IN of)
                (NP (NN IL-17))))
            (VP (MD might)
              (VP (VB be)
                (ADJP (JJ due)
                  (PP
                    (PP (TO to)
                      (NP (VBN increased) (JJ cellular) (NN activity)))
                    (CONJP (RB rather) (IN than))
                    (PP (TO to)
                      (NP (JJ cellular) (NN proliferation)))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-17))
      (VP (VBZ is)
        (VP (VBN produced)
          (ADVP (RB mainly))
          (PP (IN by)
            (NP (VBN activated) (JJ CD4+) (NN T) (NNS cells))))
        (, ,)
        (PP
          (ADVP (RB especially))
          (PP (IN for)
            (NP (NN Th1/Th0) (NNS cells)))
          (, ,) (RB not)
          (NP (DT the) (NN Th2) (NN phenotype) (CD -LSB-26) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP (PRP it))
      (VP (MD can)
        (ADVP (RB also))
        (VP (VB be)
          (VP (VBN produced)
            (PP (IN by)
              (NP (JJ CD8+) (NN T) (NNS cells)))
            (PP (IN via)
              (NP
                (NP (DT an) (NN IL-23) (VBG triggering) (NN mechanism))
                (PP (IN in)
                  (NP (JJ Gram-negative) (JJ pulmonary) (NN infection) (NN -LSB-14))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP (NN IL-17) (NN production))
      (VP (VBD was)
        (ADVP (RB significantly))
        (VP (VBN augmented)
          (PP (IN by)
            (NP
              (NP (NN T) (NNS cells))
              (VP (VBG recognizing)
                (NP (NN type) (CD II) (NN collagen))
                (PP (IN in)
                  (NP (DT a) (JJ collagen-induced) (NN arthritis) (NN model) (CD -LSB-27))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (JJ complex) (NN interaction))
        (PP (IN between)
          (NP
            (NP (NNS cells))
            (PP (IN in)
              (NP (JJ inflamed) (NN RA) (NNS joints))))))
      (VP (MD might)
        (VP (VB produce)
          (NP
            (NP (DT a) (NN variety))
            (PP (IN of)
              (NP
                (NP (JJ proinflammatory)
                  (NP (NNS cytokines))
                  (CC and)
                  (NP (NNS chemokines)))
                (, ,)
                (SBAR
                  (WHNP (WDT which))
                  (S
                    (ADVP (RB also))
                    (VP (VBP activate)
                      (NP (JJ other) (NNS cells))
                      (PP (IN in)
                        (NP (DT the) (NNS joints))))))))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP (NN example)))
    (, ,)
    (NP (NN IL-17))
    (VP (VBZ stimulates)
      (S
        (NP (JJ rheumatoid) (NNS synoviocytes))
        (VP (TO to)
          (VP (VB secrete)
            (NP
              (NP
                (NP (JJ several) (NNS cytokines))
                (PP (JJ such) (IN as)
                  (NP
                    (NP (NN IL-6))
                    (, ,)
                    (NP (NN IL-8))
                    (CC and)
                    (NP (NN tumor) (NN necrosis) (JJ factor-stimulated) (NN gene) (CD 6)))))
              (CONJP (RB as) (RB well) (IN as))
              (NP (NN prostaglandin) (NN E2)))
            (PP (IN in)
              (NP (FW vitro) (NN -LSB-12,28,29) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (NP (EX There))
      (VP (VBP are)
        (ADVP (RB as) (RB yet))
        (NP
          (NP (JJ few) (NNS data))
          (ADJP (JJ available)
            (PP (IN on)
              (NP
                (NP (DT the) (NNS agents))
                (SBAR
                  (WHNP (WDT that))
                  (S
                    (VP (VBP stimulate)
                      (NP
                        (NP (NN IL-17) (NN production))
                        (PP (IN in)
                          (NP (NN RA)))))))))))
        (, ,)
        (SBAR (IN although)
          (S
            (NP (DT some)
              (NP
                (NP (NNS cytokines))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN IL-15))
                    (CC and)
                    (NP (NN IL-23)))
                  (-RRB- -RRB-))))
            (VP (VBP have)
              (VP (VBN been)
                (VP (VBN known)
                  (S
                    (VP (TO to)
                      (VP (VB regulate)
                        (NP (NN IL-17) (NN production) (CD -LSB-13,14) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (ADVP (RB therefore))
      (VP (VBD investigated)
        (NP
          (NP
            (NP (DT the)
              (ADJP (FW in) (FW vitro))
              (NN production))
            (PP (IN of)
              (NP
                (NP (NN IL-17))
                (PP (IN in)
                  (NP
                    (NP (NN RA) (NNS PBMC))
                    (VP (VBG responding)
                      (PP (TO to)
                        (NP
                          (NP (DT a) (NN variety))
                          (PP (IN of)
                            (NP
                              (NP (NNS cytokines/chemokines))
                              (CC and)
                              (NP (NNS mitogens))))))))))))
          (CONJP (RB as) (RB well) (IN as))
          (NP
            (NP
              (NP (NN T) (NN cell) (NN receptor))
              (PRN (-LRB- -LRB-)
                (NP (NN TCR))
                (-RRB- -RRB-)))
            (NN ligation)))
        (S
          (VP (VBG using)
            (NP (JJ anti-CD3/anti-CD28))))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Our) (NNS studies))
      (VP (VBD demonstrated)
        (SBAR (IN that)
          (S
            (NP
              (NP (NN IL-15))
              (CC and)
              (NP (NN MCP-1))
              (CONJP (RB as) (RB well) (IN as))
              (NP (NN TCR) (NN ligation)))
            (ADVP (RB significantly))
            (VP (VBD increased)
              (NP
                (NP (DT the) (NN production))
                (PP (IN of)
                  (NP (NN IL-17)))
                (PP (IN in)
                  (NP (NN RA) (NNS PBMC)))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (VBG Adding)
          (NP
            (NP (NN IL-15))
            (CC or)
            (NP (NN MCP-1)))
          (PP (TO to)
            (NP (NN TCR) (NN ligation)))))
      (VP (VBD augmented)
        (NP (NN IL-17) (NN production))
        (ADVP (RBR more) (RB markedly))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP
        (NP
          (NP (NN IL-1))
          (CC and)
          (NP (NN TNF-α)))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (VBP are)
              (VP (VBN known)
                (S
                  (VP
                    (VP (TO to)
                      (VP (VB have)
                        (NP (JJ proinflammatory) (NNS properties))))
                    (CC and)
                    (VP (TO to)
                      (VP (VB be)
                        (VP (VBN increased)
                          (PP (IN in)
                            (NP (NN RA) (NNS joints))))))))))))
        (, ,))
      (VP (VBD did) (RB not)
        (VP (VB affect)
          (NP (NN IL-17) (NN production)))))
    (. .)))

(
  (S
    (S
      (S
        (NP (PRP$ Our) (NNS data))
        (VP (VBD were)
          (ADJP (JJ consistent)
            (PP (IN with)
              (NP
                (NP (DT a) (JJ recent) (NN report))
                (SBAR (IN that)
                  (S
                    (NP (NN IL-15))
                    (VP (VBD triggered)
                      (NP
                        (NP
                          (ADJP (FW in) (FW vitro))
                          (NN IL-17) (NN production))
                        (PP (IN in)
                          (NP (NN PBMC))))))))))))
      (, ,)
      (CC but)
      (S
        (NP (NN TNF-α))
        (VP (VBD did) (RB not)
          (VP (VBP do)
            (ADVP (RB so))
            (ADJP (JJ -LSB-13))))
        (-RRB- -RSB-)))
    (. .)))

(
  (S
    (SBAR (IN Although)
      (S
        (NP (EX there))
        (VP (VBD were)
          (NP
            (NP (DT no) (NNS data))
            (SBAR
              (WHNP (WDT that))
              (S
                (NP (NN MCP-1))
                (ADVP (RB directly))
                (VP (VBZ induces)
                  (NP (NN T) (NN cell) (NN activation)))))))))
    (, ,)
    (NP (PRP it))
    (VP (MD might)
      (VP (VB exert)
        (NP (NNS effects))
        (PP
          (ADVP (RB indirectly))
          (IN on)
          (NP (NN T) (NNS cells)))
        (PP (IN through)
          (NP
            (NP (DT the) (NN activation))
            (PP (IN of)
              (NP (NNS monocytes/macrophages)))
            (PP (IN in)
              (NP (NN PBMC) (NNS cultures)))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN As)
        (S
          (VP (VBN reported)
            (PP (IN for)
              (NP (JJ normal) (NNS individuals) (CD -LSB-25) (-RRB- -RSB-))))))
      (, ,)
      (NP
        (NP (NN T) (NN cell) (NN activation))
        (PP (IN through)
          (NP (JJ anti-CD3/anti-CD28))))
      (ADVP (RB also))
      (VP (VBZ increases)
        (NP
          (NP (NN IL-17) (NN induction))
          (PP (IN in)
            (NP (NN RA) (NNS PBMC))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP
            (NP (DT the) (NN signaling) (NN pathway))
            (PP (IN for)
              (NP
                (NP (DT the) (NN induction))
                (PP (IN of)
                  (NP (NNS cytokines/chemokines)))
                (PP (IN by)
                  (NP (NN IL-17))))))
          (VP (VBZ has)
            (VP (VBN been)
              (VP (VBN documented)
                (ADVP (RB widely))
                (S
                  (NP (NN -LSB-8,30,31))))))
          (-RRB- -RSB-)))
      (, ,)
      (NP (DT no) (NNS data))
      (VP (VBP have)
        (VP (VBN been)
          (ADJP (JJ available)
            (PP (IN on)
              (SBAR
                (WHADVP (WRB how))
                (S
                  (NP (NN IL-17) (NN production))
                  (VP (MD can)
                    (VP (VB be)
                      (VP (VBN regulated)
                        (PP (IN by)
                          (NP (JJ certain) (NN signaling) (NNS pathways)))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN By)
        (S
          (VP (VBG using)
            (NP (NN signal) (NN transduction) (NNS inhibitors)))))
      (, ,)
      (NP (PRP we))
      (ADVP (RB therefore))
      (VP (VBD examined)
        (SBAR
          (WHNP (WDT which))
          (S
            (NP (NN signaling) (NN pathway))
            (VP (VBD was)
              (ADVP (RB mainly))
              (VP (VBN involved)
                (PP (IN in)
                  (NP
                    (NP (DT the) (NN induction))
                    (PP (IN of)
                      (NP (NN IL-17)))
                    (PP (IN in)
                      (NP (NN RA) (NNS PBMC)))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD identified)
        (SBAR (IN that)
          (S
            (NP
              (NP (JJ anti-CD3-induced) (NN IL-17) (NN production))
              (PP (IN in)
                (NP (NN RA) (NNS PBMC))))
            (VP (VBD was)
              (ADVP (RB significantly))
              (VP (VBN hampered)
                (PP (IN by)
                  (NP
                    (NP (DT the) (NN PI3K) (NN inhibitor) (NN LY294002))
                    (CC and)
                    (NP
                      (NP (DT the) (JJ NF-κB) (NN inhibitor) (NN PDTC))
                      (PP (TO to)
                        (NP
                          (NP (JJ comparable) (NNS levels))
                          (PP (IN of)
                            (NP
                              (NP (JJ basal) (NN production))
                              (PP (IN without)
                                (NP (NN stimulation))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (ADVP (RB also))
      (VP (VBD found)
        (SBAR (IN that)
          (S
            (NP (JJ anti-CD3-induced) (NN IL-17) (NN production))
            (VP (VBD was)
              (VP (VBN downregulated)
                (PP (IN by)
                  (NP
                    (NP (DT the) (NN addition))
                    (PP (IN of)
                      (NP
                        (NP (NN SB203580))
                        (, ,)
                        (NP (DT a) (NN p38) (NN MAPK) (NN inhibitor))))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ is)
        (ADJP (JJ interesting)
          (SBAR (IN that)
            (S
              (NP
                (NP (DT a) (NN series))
                (PP (IN of)
                  (NP (NN evidence))))
              (VP (VBZ supports)
                (NP
                  (NP (NN crosstalk))
                  (PP (IN between)
                    (NP
                      (NP (NN NF-κB))
                      (CC and)
                      (NP (NN p38)))))))))))
    (. .)))

(
  (S
    (S
      (S
        (PP (IN In)
          (NP (NNS myocytes)))
        (, ,)
        (NP (NN IκB) (NN kinase-β))
        (VP (VBZ is)
          (VP (VBN activated)
            (PP (IN by)
              (NP (NN p38) (NN -LSB-32)))))
        (-RRB- -RSB-))
      (, ,)
      (CC and)
      (S
        (NP (DT the) (VBN activated) (NN p38))
        (VP (MD can)
          (VP (VB stimulate)
            (NP (NN NF-κB))
            (PP (IN by)
              (NP
                (NP (DT a) (NN mechanism))
                (VP (VBG involving)
                  (NP (NN histone) (NN acetylase) (JJ p300/CREB-binding) (NN protein) (NN -LSB-33) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Our) (NNS results))
      (VP (VBD revealed)
        (SBAR (IN that)
          (S
            (NP
              (NP (NN p38) (NN MAPK))
              (NN activation))
            (VP (VBD was) (RB not)
              (VP (VBN affected)
                (PP (IN by)
                  (NP (NN LY294002))))
              (, ,)
              (SBAR (IN whereas)
                (S
                  (NP (JJ NF-κB) (NN binding) (NN activity))
                  (VP (VBD was)
                    (VP (VBN decreased)
                      (PP (IN by)
                        (NP
                          (NP (NN LY294002))
                          (, ,)
                          (SBAR
                            (WHNP (WDT which))
                            (S
                              (VP (VBD provided)
                                (NP
                                  (NP (DT the) (NN evidence))
                                  (PP (IN for)
                                    (NP
                                      (NP (DT a) (NN p38) (NN MAPK) (NN pathway))
                                      (ADJP (JJ independent)
                                        (PP (IN of)
                                          (NP (NN PI3K) (NN activation)))))))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ direct) (NN relationship))
        (PP (IN between)
          (NP
            (NP (NN p38))
            (CC and)
            (NP (NN NF-κB))))
        (PP (IN for)
          (NP (NN IL-17) (NN production))))
      (VP (VBZ needs)
        (S
          (VP (TO to)
            (VP (VB be)
              (VP (VBN studied)
                (PP (IN in)
                  (NP (JJ future) (NNS experiments)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN search))
        (PP (IN for)
          (NP
            (NP (DT a) (JJ downstream) (NN pathway))
            (PP (IN of)
              (NP (NN PI3K))))))
      (VP (VBD seemed)
        (S
          (VP (TO to)
            (VP (VB have)
              (NP
                (NP
                  (NP (DT a) (JJ maximal) (NN response))
                  (PP (IN of)
                    (NP
                      (NP (NN Akt) (NN activation))
                      (PP (IN at)
                        (NP (CD 1) (NN hour))))))
                (CC and)
                (NP
                  (NP (DT a) (JJ gradual) (NN loss))
                  (PP (IN of)
                    (NP (NN activity)))))
              (PP (IN at)
                (NP (CD 2) (NNS hours))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN fact)
        (SBAR (IN that)
          (S
            (NP (NN Akt))
            (VP (VBZ is)
              (VP (VBN phosphorylated)
                (PP (IN upon)
                  (NP (JJ anti-CD3) (NN stimulation))))))))
      (VP (VBZ suggests)
        (NP
          (NP (DT the) (JJ possible) (NN involvement))
          (PP (IN of)
            (NP (NN PI3K)))
          (PP (IN in)
            (NP
              (NP (DT the) (NN induction))
              (PP (IN of)
                (NP (NN IL-17)))
              (PP (IN in)
                (NP (NN RA))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP
        (NP (NN view))
        (PP (IN of)
          (NP (DT the) (NN fact)
            (SBAR (IN that)
              (S
                (NP (NN NF-κB))
                (VP (VBD was)
                  (ADVP (RB also))
                  (VP (VBN activated)
                    (PP (IN by)
                      (NP
                        (NP
                          (ADJP (JJ anti-CD3/anti-CD28)))
                        (, ,)
                        (NP (NN IL-15))
                        (CC or)
                        (NP (NNS mitogens))))
                    (PP (IN in)
                      (NP (PRP$ our) (NNS experiments)))))))))))
    (, ,)
    (NP (PRP it))
    (VP (VBZ is)
      (ADJP (RBS most) (JJ likely)
        (SBAR (IN that)
          (S
            (NP (DT the) (JJ NF-κB) (NN pathway))
            (VP (VBZ is)
              (ADVP (RB also))
              (ADVP (RB actively))
              (VP (VBN involved)
                (PP (IN in)
                  (NP
                    (NP (DT the) (NN induction))
                    (PP (IN of)
                      (NP (NN IL-17)))
                    (PP (IN in)
                      (NP (NN RA) (NNS PBMC)))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP
        (NP (DT the) (NN AP-1) (NN signal) (NN transduction) (NN pathway))
        (, ,)
        (NP
          (NP (DT another) (JJ important) (NN signaling) (NN pathway))
          (PP (IN for)
            (NP (NNS cytokines/chemokines))))
        (, ,))
      (VP (VBD was) (RB not)
        (VP (VBN activated)
          (PP (IN in)
            (NP (PRP$ our) (NNS experiments)))
          (PRN (-LRB- -LRB-)
            (S
              (NP (NNS data))
              (VP (RB not) (VBN shown)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP
            (NP (NN PI3K))
            (CC and)
            (NP
              (NP (PRP$ its) (JJ downstream) (NN kinase) (NN Akt))
              (PP (IN in)
                (NP
                  (NP (NN association))
                  (PP (IN with)
                    (NP (NN NF-κB)))))))
          (VP (VBP have)
            (VP (VBN been)
              (VP (VBN reported)
                (S
                  (VP (TO to)
                    (VP (VB deliver)
                      (NP
                        (NP (NN activating) (NNS signals))
                        (PP (IN in)
                          (NP (JJ many) (NN cell) (NNS types))))))))))))
      (, ,)
      (NP
        (NP (DT the) (NNS data))
        (PP (IN on)
          (NP (DT the) (NN signal) (NN inducing) (NN IL-17))))
      (VP (VBP are)
        (VP (VBG lacking))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Our) (NNS data))
      (ADVP (RB clearly))
      (VP (VBD demonstrated)
        (SBAR (IN that)
          (S
            (NP
              (NP (NN PI3K/Akt))
              (CC and)
              (NP (JJ resultant) (NN NF-κB) (NN activation)))
            (VP (MD could)
              (VP (VB be)
                (NP (DT an) (JJ important) (NN arbitrator))
                (PP (IN of)
                  (NP
                    (NP (DT the) (NN upregulation))
                    (PP (IN of)
                      (NP
                        (NP (NN IL-17))
                        (PP (IN in)
                          (NP (NN RA)))))))
                (, ,)
                (PP (IN on) (DT the) (NN basis) (IN of)
                  (NP
                    (NP (PRP$ our) (NNS experiments))
                    (VP (VBG showing)
                      (NP
                        (NP (JJ simultaneous) (NN blocking))
                        (PP (IN of)
                          (NP
                            (NP (JJ NF-κB) (NN binding) (NN activity))
                            (PP (IN in)
                              (NP (DT the) (NN IL-17) (NN promoter)))))
                        (PP (IN by)
                          (NP
                            (NP (NN PDTC))
                            (CC and)
                            (NP (NN LY294002))))))))))))))
    (. .)))

(
  (S
    (PP (VBG Considering)
      (NP
        (NP (PRP$ its) (JJ proinflammatory) (NNS activities))
        (CC and)
        (NP
          (NP (JJ successful) (NN induction))
          (PP (IN of)
            (NP
              (NP (NN anti-IL-17))
              (PP (IN for)
                (NP (JJ ameliorating) (NN arthritis)))))
          (PP (IN in)
            (NP (NN animal) (NNS models) (CD -LSB-2,6,34-36) (-RRB- -RSB-))))))
    (, ,)
    (S
      (VP (VBG understanding)
        (NP (DT the) (NN IL-17) (NN signaling) (NN pathway))))
    (VP (VBZ is)
      (NP
        (NP (DT an) (JJ important) (NN element))
        (PP (IN of)
          (S
            (VP (VBG developing)
              (NP (JJ new) (VBN targeted) (NNS therapies))
              (PP (IN in)
                (NP (NN RA))))))))
    (. .)))

(
  (S
    (NP (NNS Conclusions))))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP have)
        (VP (VBN detected)
          (NP
            (NP (DT a)
              (ADJP (RBR more) (JJ pronounced))
              (NN production))
            (PP (IN of)
              (NP (NN IL-17)))
            (PP (IN from)
              (NP (NN RA) (NN PBMC))))
          (PP (IN in)
            (NP
              (NP (NN response))
              (PP (TO to)
                (NP
                  (NP (NN IL-15))
                  (CC and)
                  (NP (NN MCP-1))
                  (CONJP (RB as) (RB well) (IN as))
                  (NP
                    (NP (NN stimulation))
                    (PP (IN by)
                      (NP (JJ anti-CD3/anti-CD28)))))))))))
    (. .)))

(
  (S
    (NP (PRP We))
    (VP (VBP have)
      (ADVP (RB also))
      (VP (VBN shown)
        (SBAR (IN that)
          (S
            (NP
              (NP (NN upregulation))
              (PP (IN of)
                (NP (NN IL-17)))
              (PP (IN by)
                (NP
                  (NP (VBN activated) (NN T) (NNS cells))
                  (PP (IN in)
                    (NP
                      (NP (NNS patients))
                      (PP (IN with)
                        (NP (NN RA))))))))
            (VP (MD could)
              (VP (VB be)
                (NP
                  (NP (DT the) (NN result))
                  (PP (IN of)
                    (NP (NN activation))))
                (PP (IN via)
                  (NP
                    (NP (DT the) (NN PI3K/Akt) (NN pathway))
                    (PP (IN with)
                      (NP (JJ resultant) (NN NF-κB) (NN activation)))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP$ Our) (NNS data))
      (VP
        (VP (VBP provide)
          (NP
            (NP (NNS insights))
            (PP (IN into)
              (NP
                (NP (JJ cellular) (NNS mechanisms))
                (PP (IN of)
                  (NP
                    (NP (DT the) (NN regulation))
                    (PP (IN of)
                      (NP
                        (NP (NN IL-17) (NN production))
                        (PP (IN in)
                          (NP (NN RA)))))))))))
        (, ,)
        (CC and)
        (VP (VBP highlight)
          (NP
            (NP (DT the) (NN role))
            (PP (IN of)
              (NP (NN T) (NNS cells)))
            (, ,)
            (SBAR
              (WHNP (WDT which))
              (S
                (VP (VBZ has)
                  (ADVP (RB hitherto))
                  (VP (VBN been)
                    (VP (VBN neglected)
                      (PP (IN in)
                        (NP (NN RA) (NN pathogenesis))))))))))))
    (. .)))

(
  (S
    (S
      (PP
        (ADVP (RB Together))
        (IN with)
        (NP
          (NP (JJ recent) (NNS data))
          (PP (IN on)
            (NP
              (NP (DT the) (JJ successful) (NN introduction))
              (PP (IN of)
                (NP (NN anti-IL-17)))
              (PP (IN in)
                (NP (NN RA)))))))
      (, ,)
      (NP (PRP$ our) (NNS results))
      (VP (VBP have)
        (VP (VBN added)
          (NP
            (NP (NN information))
            (PP (IN for)
              (NP
                (NP (DT the) (JJ future) (JJ molecular) (NN targeting))
                (PP (IN of)
                  (NP
                    (NP (JJ new) (JJ therapeutic) (NNS applications))
                    (PP (IN in)
                      (NP (NN RA)))))))))))
    (. .)))

(
  (S
    (NP (NNS Abbreviations))))

(
  (S
    (S
      (UCP
        (NP (NN AP-1))
        (, ,)
        (NP
          (NP
            (NP
              (NP
                (NP (NN activator) (NN protein-1))
                (: ;)
                (NP (NN BSA) (JJ =) (JJ bovine) (NN serum) (NN albumin))
                (: ;)
                (NP (NN EMSA) (JJ =) (JJ electrophoretic) (NN mobility-shift) (NN assay))
                (: ;)
                (NP (NN GAPDH) (JJ =) (NN glyceraldehyde-3-phosphate) (NN dehydrogenase))
                (: ;)
                (NP (NN IL) (JJ =) (NN interleukin))
                (: ;)
                (NP (NN MAPK) (JJ =) (JJ mitogen-activated) (NN protein) (NN kinase))
                (: ;)
                (NP (NN MCP-1) (JJ =) (NN monocyte) (NN chemoattractant) (NN protein-1))
                (: ;)
                (NP (NN MIP) (JJ =) (NN macrophage) (JJ inflammatory) (NN protein))
                (: ;) (CD NF-κB))
              (JJ =) (JJ nuclear) (NN factor) (NN κB))
            (: ;) (NN OA) (JJ =) (NN osteoarthritis))
          (: ;)
          (NP (NN PBMC) (JJ =) (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
          (: ;)
          (NP (NN PDTC) (JJ =) (NN pyrrolidine) (NN dithiocarbamate))
          (: ;)
          (NP (NN PHA) (JJ =) (NN phytohemagglutinin))
          (: ;)
          (NP (NN PI3K) (JJ =) (NN phosphoinositide) (NN 3-kinase))
          (: ;)
          (NP (NN RA) (JJ =) (JJ rheumatoid) (NN arthritis))
          (: ;)
          (NP (NN TGF) (JJ =) (NN transforming) (NN growth) (NN factor))
          (: ;)
          (NP (NN Th) (JJ =) (NN T) (NN helper))
          (: ;)
          (NP (NN TNF) (JJ =) (NN tumor) (NN necrosis) (NN factor)))))
    (. .)))

(
  (S
    (NP (VBG Competing) (NNS interests))))

(
  (S
    (S
      (NP (DT The) (NN author) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))
      (VP (VB declare)
        (SBAR (IN that)
          (S
            (NP (PRP they))
            (VP (VBP have)
              (NP (DT no) (VBG competing) (NNS interests)))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Authors) (POS '))
      (NNS contributions))))

(
  (S
    (S
      (NP (NN KWK))
      (VP
        (VP (VBD performed)
          (NP (DT the) (JJ cellular) (JJ immune) (NN response) (NNS studies)))
        (CC and)
        (VP (VBD participated)
          (PP (IN in)
            (NP (DT the) (NNS immunoassays))))))
    (. .)))

(
  (S
    (S
      (NP (NN MLC))
      (VP
        (VP (VBD participated)
          (PP (IN in)
            (NP
              (NP (DT the) (NN design))
              (PP (IN of)
                (NP (DT the) (NN study))))))
        (CC and)
        (VP (VBD performed)
          (NP (DT the) (JJ statistical) (NN analysis)))))
    (. .)))

(
  (S
    (S
      (NP (NN MKP))
      (VP (VBD participated)
        (PP (IN in)
          (NP
            (NP (DT the) (NN isolation))
            (PP (IN of)
              (NP (DT the) (NNS cells)))))))
    (. .)))

(
  (S
    (S
      (NP (NN CHY))
      (VP (VBN drafted)
        (NP (DT the) (NN manuscript))))
    (. .)))

(
  (S
    (S
      (NP (NN SHP))
      (VP (VBD participated)
        (PP
          (PP (IN in)
            (NP (DT the) (JJ molecular) (NN biology)))
          (CC and)
          (PP (IN in)
            (NP (DT the) (NN PCR))))))
    (. .)))

(
  (S
    (S
      (NP (NN SHL))
      (VP
        (VP (VBD conceived)
          (NP (DT the) (NN study)))
        (, ,)
        (VP (VBD participated)
          (PP (IN in)
            (NP (PRP$ its)
              (NP (NN design))
              (CC and)
              (NP (NN coordination)))))
        (CC and)
        (VP (VBD helped)
          (PP (TO to)
            (NP (JJ draft) (DT the) (NN manuscript))))))
    (. .)))

(
  (S
    (S
      (NP (NN HYK))
      (VP (VBD helped)
        (PP (TO to)
          (NP (JJ draft) (DT the) (NN manuscript)))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NNS authors))
      (VP
        (VP (VBN read))
        (CC and)
        (VP (JJ approved)
          (NP (DT the) (JJ final) (NN manuscript)))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure))
      (CC and)
      (NP (NN Table))
      (NP (NNS captions)))))

(
  (S
    (NP
      (NP (NN Figure) (CD 1))
      (: :)
      (NP
        (NP (NNS Levels))
        (PP (IN of)
          (NP
            (NP
              (NP
                (NP (NN interleukin))
                (PRN (-LRB- -LRB-)
                  (NP (NN IL))
                  (-RRB- -RRB-)))
              (CD -17) (NN production))
            (PP (IN in)
              (NP
                (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
                (PP (IN from)
                  (NP
                    (NP
                      (NP (NNS patients))
                      (PP (IN with)
                        (NP (JJ rheumatoid) (NN arthritis)))
                      (PRN (-LRB- -LRB-)
                        (NP (NN RA))
                        (: ;)
                        (NP (NN n) (JJ =) (CD 24))
                        (-RRB- -RRB-)))
                    (, ,)
                    (NP
                      (NP (NNS patients))
                      (PP (IN with)
                        (NP
                          (NP (NN osteoarthritis))
                          (PRN (-LRB- -LRB-)
                            (NP (NN OA))
                            (-RRB- -RRB-))))
                      (PRN (-LRB- -LRB-)
                        (NP (NN n) (JJ =) (CD 14))
                        (-RRB- -RRB-)))
                    (CC and)
                    (NP
                      (NP (JJ normal) (NNS individuals))
                      (PRN (-LRB- -LRB-)
                        (NP (NN n) (JJ =) (CD 14))
                        (-RRB- -RRB-))))))))))
      (. .))))

(
  (S
    (S
      (NP (DT Each) (JJ peripheral) (NN blood) (JJ mononuclear) (NN cell))
      (VP (VBD was)
        (VP (VBN stimulated)
          (PP (IN for)
            (NP
              (NP (CD 24) (NNS hours))
              (PP
                (PP (IN with))
                (CC or)
                (PP (IN without)
                  (NP
                    (NP (NN phytohemagglutinin))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NN PHA))
                        (: ;)
                        (NP (CD 5) (NN μg/ml)))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IL-17))
      (VP (VBD was)
        (VP (VBN measured)
          (PP (IN in)
            (NP (NN culture) (NNS supernatants)))
          (PP (IN by)
            (NP (JJ sandwich) (JJ enzyme-linked) (JJ immunosorbent) (NN assay))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Data))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (NN means))
              (CC and)
              (NP (NN SEM)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD One) (JJ representative) (NN result))
        (PP (IN of)
          (NP (CD five) (JJ independent) (NNS experiments))))
      (VP (VBZ is)
        (VP (VBN shown))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Student) (POS 's))
        (NN t-test))
      (VP (VBD was)
        (VP (VBN used)
          (S
            (VP (TO to)
              (VP (VB compare)
                (NP (DT each) (NN group))))))))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB *))
        (, ,)
        (NP (NN P))
        (VP (JJ <)
          (NP (CD 0.05))))
      (: ;)
      (S
        (NP (NN **))
        (, ,)
        (NP (NN P))
        (VP (JJ <)
          (NP (CD 0.001)))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 2))
      (: :)
      (NP
        (NP (NN Production))
        (PP (IN of)
          (NP (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -17)))
        (PP (IN by)
          (NP
            (NP
              (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP (NN PBMC))
                (-RRB- -RRB-)))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP
                    (NP (JJ rheumatoid) (NN arthritis))
                    (PRN (-LRB- -LRB-)
                      (NP (NN RA))
                      (-RRB- -RRB-)))))))))
      (. .))))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
        (NN Production))
      (PP (IN of)
        (NP (NN IL-17)))
      (PP (IN by)
        (NP (NN cytokine) (NN induction)))
      (. .))))

(
  (S
    (S
      (NP
        (NP (NN PBMC))
        (PP (IN from)
          (NP
            (NP (NNS patients))
            (PP (IN with)
              (NP (NN RA))))))
      (VP (VBD were)
        (VP (VBN stimulated)
          (PP (IN for)
            (NP (CD 24) (NNS hours)))
          (PP (IN with)
            (NP
              (NP
                (NP (NN IL-15))
                (PRN (-LRB- -LRB-)
                  (NP (CD 10) (NN ng/ml))
                  (-RRB- -RRB-)))
              (, ,)
              (NP
                (NP (NN IL-1β))
                (PRN (-LRB- -LRB-)
                  (NP (CD 10) (NN ng/ml))
                  (-RRB- -RRB-)))
              (, ,)
              (NP
                (NP (NN tumor) (NN necrosis) (NN factor-α))
                (PRN (-LRB- -LRB-)
                  (NP (CD TNF-α) (: ;) (CD 10) (NN ng/ml))
                  (-RRB- -RRB-)))
              (, ,)
              (NP
                (NP (NN IL-18))
                (PRN (-LRB- -LRB-)
                  (NP (CD 10) (NN ng/ml))
                  (-RRB- -RRB-)))
              (CC and)
              (NP
                (NP (NN transforming) (NN growth) (NN factor-β))
                (PRN (-LRB- -LRB-)
                  (NP (CD TGF-β) (: ;) (CD 10) (NN ng/ml))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Levels))
        (PP (IN of)
          (NP (NN IL-17))))
      (VP (VBD were)
        (VP (VBN measured)
          (PP (IN in)
            (NP (NN culture) (NNS supernatants)))
          (PP (IN by)
            (NP (JJ enzyme-linked) (JJ immunosorbent) (NN assay))))))
    (. .)))

(
  (S
    (S
      (NP (DT Each) (NN value))
      (VP (VBZ represents)
        (NP
          (NP (DT the)
            (NP (NN mean))
            (CC and)
            (NP (NN SEM)))
          (PP (IN of)
            (NP (CD three) (JJ independent) (NNS experiments))))))
    (. .)))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
        (NN Production))
      (PP (IN of)
        (NP (NN IL-17)))
      (PP (IN by)
        (NP (NN chemokine) (NN induction)))
      (. .))))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBD were)
        (VP (VBN cultured)
          (PP (IN in)
            (NP
              (NP (DT the) (NN presence))
              (PP (IN of)
                (NP
                  (NP
                    (NP (NN monocyte) (NN chemoattractant) (NN protein-1))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NN MCP-1))
                        (: ;)
                        (NP (CD 10) (NN ng/ml)))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP (NN macrophage) (JJ inflammatory) (NN protein-1α))
                    (PRN (-LRB- -LRB-)
                      (NP (NN MIP-1α) (: ;) (CD 10) (NN ng/ml))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP (NN MIP-1β))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 10) (NN ng/ml))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP
                      (NP
                        (NP (NN IL-6))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 10) (NN ng/ml))
                          (-RRB- -RRB-)))
                      (CC and)
                      (NP (NN IL-8)))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 10) (NN ng/ml))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN *))
      (, ,)
      (NP (NN P))
      (NP (JJR <) (CD 0.05)))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 3))
      (: :)
      (S
        (NP
          (NP (NNS Effects))
          (PP (IN of)
            (NP
              (NP (NN protein) (NN kinase) (NNS inhibitors))
              (CC and)
              (NP (JJ anti-rheumatic) (NN drug))))
          (PP (IN on)
            (NP (NN anti-CD3))))
        (VP (VBD triggered)
          (NP
            (NP
              (NP
                (NP (NN interleukin))
                (PRN (-LRB- -LRB-)
                  (NP (NN IL))
                  (-RRB- -RRB-)))
              (CD -17) (NN production))
            (PP (IN by)
              (NP
                (NP
                  (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
                  (PRN (-LRB- -LRB-)
                    (NP (NN PBMC))
                    (-RRB- -RRB-)))
                (PP (IN from)
                  (NP
                    (NP (NNS patients))
                    (PP (IN with)
                      (NP (JJ rheumatoid) (NN arthritis))))))))))
      (. .))))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBN pretreated)
        (PP (IN for)
          (NP (CD 1) (NN hour)))
        (PP (IN with)
          (NP
            (NP
              (NP (NN pyrrolidine) (NN dithiocarbamate))
              (PRN (-LRB- -LRB-)
                (NP (NN PDTC) (: ;) (CD 300) (NN μM))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (NN curcumin))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN μM))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP
                (NP
                  (NP
                    (NP (NN LY294002))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 20) (NN μM))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP (NN wortmannin))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 200) (NN nM))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP (NN Cyclosporin) (NN A))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 500) (NN ng/ml))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP (NN dexamethasone))
                    (PRN (-LRB- -LRB-)
                      (NP (NN DEX) (: ;) (CD 100) (NN nM))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP (NN FK506))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 100) (NN ng/ml))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP (NN rapamycin))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 10) (NN ng/ml))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP
                    (NP (NN SB203580))
                    (PRN (-LRB- -LRB-)
                      (NP (CD 10) (NN nM))
                      (-RRB- -RRB-)))
                  (CC or)
                  (NP (NN PD98059)))
                (PRN (-LRB- -LRB-)
                  (NP (CD 20) (NN μM))
                  (-RRB- -RRB-)))
              (PP (IN in)
                (NP
                  (NP (NN combination))
                  (PP (IN with)
                    (NP
                      (NP (JJ anti-CD3) (NN antibody))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 5) (NN μg/ml))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Culture) (NN supernatant))
      (VP (VBD was)
        (VP (VBN assayed)
          (PP (IN for)
            (NP (NN IL-17)))
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (PP (IN in)
                  (NP (DT the)
                    (NP
                      (NP (NNS Materials))
                      (CC and)
                      (NP (NNS methods)))
                    (NN section)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT Each) (NN value))
      (VP (VBZ represents)
        (NP
          (NP (DT the)
            (NP (NN mean))
            (CC and)
            (NP (NN SEM)))
          (PP (IN of)
            (NP (CD three) (JJ independent) (NNS experiments))))))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB *))
        (, ,)
        (NP (NN P))
        (VP (JJ <)
          (NP (CD 0.05))))
      (: ;)
      (S
        (NP (NN **))
        (, ,)
        (NP (NN P))
        (VP (JJ <)
          (NP (CD 0.005)))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 4))
      (: :)
      (NP
        (NP (JJ Dose-dependent) (NNS effects))
        (PP (IN of)
          (NP
            (NP (NN LY294002))
            (CC or)
            (NP
              (NP (NN pyrrolidine) (NN dithiocarbamate))
              (PRN (-LRB- -LRB-)
                (NP (NN PDTC))
                (-RRB- -RRB-)))))
        (PP (IN in)
          (NP
            (NP
              (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP (NN PBMC))
                (-RRB- -RRB-)))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP
                    (NP (JJ rheumatoid) (NN arthritis))
                    (PRN (-LRB- -LRB-)
                      (NP (NN RA))
                      (-RRB- -RRB-)))))))))
      (. .))))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
      (NP
        (NP (NN Effect))
        (PP (IN of)
          (NP (NNS inhibitors)))
        (PP (IN on)
          (NP (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -17))))
      (VP (VB release)
        (PP (IN by)
          (NP
            (NP (JJ anti-CD3-stimulated) (NN PBMC))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP (NN RA)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (-LRB- -LRB-) (NN b) (-RRB- -RRB-) (NNS Effects))
        (PP (IN of)
          (NP
            (NP (NN LY294002))
            (CC or)
            (NP (NN PDTC))))
        (PP (IN on)
          (NP (NN PBMC) (NN viability)))))
    (. .)))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBD were)
        (VP (VBN cultured)
          (PP (IN at)
            (NP
              (NP (DT a) (NN concentration))
              (PP (IN of)
                (NP
                  (NP (CD 2) (NN ×) (CD 105) (NNS cells))
                  (PP (IN per)
                    (NP (NN well)))))))
          (PP (IN with)
            (NP
              (NP
                (NP (NN medium))
                (, ,)
                (NP (NN anti-CD3))
                (, ,)
                (NP (NN anti-CD3))
                (CC and)
                (NP (NN LY294002)))
              (CC or)
              (NP (NN PDTC))))
          (PP (IN under)
            (NP
              (NP (DT the) (NNS conditions))
              (VP (VBN described)
                (PP (IN in)
                  (NP (DT the)
                    (NP
                      (NP (NNS Materials))
                      (CC and)
                      (NP (NNS methods)))
                    (NN section)))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (CD 24) (NNS hours))
        (PP (IN of)
          (NP (NN treatment)))))
    (, ,)
    (NP (NN cell) (NN viability))
    (VP (VBD was)
      (VP
        (VP (VBN assessed)
          (PP (IN by)
            (NP (DT the)
              (NP (NN trypan) (JJ blue) (NN dye) (NN exclusion))
              (NN method))))
        (CC and)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT a) (NN percentage))
              (PP (IN with)
                (NP
                  (NP (DT the) (NN formula) (CD 100) (NN ×))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN number))
                      (PP (IN of)
                        (NP
                          (NP (JJ viable) (NN cells/number))
                          (PP (IN of)
                            (NP
                              (ADJP (CC both)
                                (ADJP (JJ viable))
                                (CC and)
                                (ADJP (JJ dead)))
                              (NNS cells))))))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 5))
      (: :)
      (NP
        (NP (NNS Effects))
        (PP (IN of)
          (NP
            (NP (NN LY294002))
            (CC or)
            (NP
              (NP (NN pyrrolidine) (NN dithiocarbamate))
              (PRN (-LRB- -LRB-)
                (NP (NN PDTC))
                (-RRB- -RRB-)))))
        (PP (IN on)
          (NP
            (NP
              (NP (JJ anti-CD3) (JJ antibody-triggered) (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -17))
              (NN mRNA) (NN expression))
            (PP (IN by)
              (NP
                (NP
                  (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
                  (PRN (-LRB- -LRB-)
                    (NP (NN PBMC))
                    (-RRB- -RRB-)))
                (PP (IN from)
                  (NP
                    (NP (NNS patients))
                    (PP (IN with)
                      (NP (JJ rheumatoid) (NN arthritis))))))))))
      (. .))))

(
  (S
    (S
      (NP (NN PBMC))
      (VP (VBD were)
        (VP (VBN cultured)
          (PP (IN with)
            (NP (NN medium)))
          (ADVP
            (ADVP (RB only))
            (PRN (-LRB- -LRB-)
              (NP (NNP lane) (CD 1))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP
              (NP (JJ anti-CD3) (NN antibody))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (CD 1) (NN μg/ml))
                  (: ;)
                  (NP (NNP lane) (CD 2)))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (JJ anti-CD3) (NN antibody))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (CD 10) (NN μg/ml))
                  (: ;)
                  (NP (NNP lane) (CD 3)))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP
                (NP
                  (NP (JJ anti-CD3) (NN antibody))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 10) (NN μg/ml))
                    (-RRB- -RRB-)))
                (CC plus)
                (NP (NN LY294002)))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (CD 20) (NN μM))
                  (: ;)
                  (NP (NNP lane) (CD 4)))
                (-RRB- -RRB-)))
            (CC or)
            (NP
              (NP
                (NP
                  (NP (JJ anti-CD3) (NN antibody))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 10) (NN μg/ml))
                    (-RRB- -RRB-)))
                (CC plus)
                (NP (NN PDTC)))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (CD 300) (NN μM))
                  (: ;)
                  (NP (NNP lane) (CD 5)))
                (-RRB- -RRB-))))
          (PP (IN for)
            (NP (CD 12) (NNS hours))))))
    (: ;)
    (S
      (NP (NNP lane) (CD 6))
      (VP (VBZ shows)
        (NP (DT a) (JJ negative) (NN control))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Total) (NN RNA))
        (PRN (-LRB- -LRB-)
          (NP (CD 2) (NN μg))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (VP (VBN used)
          (PP (IN for)
            (NP (NN cDNA) (NN synthesis)))
          (PP (IN in)
            (NP
              (NP (DT a) (NN volume))
              (PP (IN of)
                (NP (CD 20) (NN μl))))))))
    (: ;)
    (S
      (NP
        (NP (CD 1) (NN μl))
        (PP (IN of)
          (NP (DT the) (VBN synthesized) (NN cDNA))))
      (VP (VBD was)
        (VP (VBN used)
          (PP (IN for)
            (NP (JJ reverse) (NN transcription–polymerase) (NN chain) (NN reaction)))
          (SBAR (IN as)
            (S
              (VP (VBN described)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN PCR) (NN reaction) (NN product))
        (PRN (-LRB- -LRB-)
          (NP (CD 25) (NN μl))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (VP (VBN separated)
          (PP (IN on)
            (NP (DT an) (NN agarose) (NN gel) (NN containing) (NN ethidium) (NN bromide))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ relative) (NNS intensities))
        (PP (IN of)
          (NP (DT the) (NNS bands))))
      (VP (VBD were)
        (VP (VBN revealed)
          (PP (IN under)
            (NP (NN UV) (NN radiation))))))
    (. .)))

(
  (S
    (S
      (NP (NN Figure) (CD 6))
      (: :)
      (NP
        (NP
          (NP (NN Activation))
          (PP (IN of)
            (NP (JJ phosphorylated) (NN Akt)))
          (PP (IN after)
            (NP
              (NP
                (NP (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -17))
                (NN induction))
              (PP (IN by)
                (NP (JJ anti-CD3) (NN antibody))))))
        (, ,)
        (CC and)
        (NP
          (NP (PRP$ its) (NN inhibition))
          (PP (IN by)
            (NP (NN LY294002))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Peripheral) (NN blood) (JJ mononuclear) (NNS cells))
      (VP (VBD were)
        (VP (VBN cultured)
          (PP (IN with)
            (NP
              (NP (NN medium))
              (ADVP (RB only))))
          (PRN (-LRB- -LRB-)
            (NP (NNP lane) (CD 1))
            (-RRB- -RRB-))
          (, ,)
          (NP
            (NP
              (NP (JJ anti-CD3) (NN antibody))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (CD 10) (NN μg/ml))
                  (: ;)
                  (NP (NNP lane) (CD 2)))
                (-RRB- -RRB-)))
            (CC or)
            (NP
              (NP
                (NP
                  (NP (JJ anti-CD3) (NN antibody))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 10) (NN μg/ml))
                    (-RRB- -RRB-)))
                (CC plus)
                (NP (NN LY294002)))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (CD 20) (NN μM))
                  (: ;)
                  (NP (NNP lane) (CD 3)))
                (-RRB- -RRB-))))
          (PP (IN for)
            (NP (CD 10–120) (NN min))))))
    (. .)))

(
  (S
    (S
      (NP (NN Cell) (NNS lysates))
      (VP (VBD were)
        (VP (VBN analyzed)
          (PP (IN for)
            (NP
              (NP (NN Akt) (NN activation))
              (PP (IN by)
                (NP
                  (NP (NN western) (NN blot) (NN analysis))
                  (PP (IN of)
                    (NP
                      (NP
                        (ADJP
                          (ADJP (JJ total))
                          (CC and)
                          (ADJP (JJ Ser473-phosphorylated)))
                        (NN Akt))
                      (PRN (-LRB- -LRB-)
                        (NP (NN P-Akt))
                        (-RRB- -RRB-))))))))
          (S
            (VP (VBG using)
              (NP (JJ specific) (NNS antibodies)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Levels))
        (PP (IN of)
          (NP (JJ phosphorylated) (NN Akt))))
      (VP (VBD were)
        (VP (VBN compared)
          (PP (IN at)
            (NP (DT each) (NN time) (NN point)))
          (, ,)
          (PP (IN after)
            (NP
              (NP (NN normalization))
              (PP (TO to)
                (NP
                  (NP
                    (NP (NN Akt))
                    (CC and)
                    (NP (NN β-actin)))
                  (PP (IN in)
                    (NP (DT the) (JJ same) (NN sample))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (JJ representative) (NN example))
        (PP (IN of)
          (NP (CD three) (JJ separate) (NNS experiments))))
      (VP (VBZ is)
        (VP (VBN shown))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 7))
      (: :)
      (NP
        (NP (NNS Effects))
        (PP (IN of)
          (NP
            (NP (NN anti-CD3))
            (CC plus)
            (NP (NN anti-CD28))))
        (PP (IN on)
          (NP
            (NP
              (NP (JJ NF-κB) (NN complex))
              (PP (IN in)
                (NP
                  (NP (JJ nuclear) (NNS extracts))
                  (PP (IN of)
                    (NP
                      (NP
                        (NP
                          (NP (JJ rheumatoid) (NN arthritis))
                          (PRN (-LRB- -LRB-)
                            (NP (NN RA))
                            (-RRB- -RRB-)))
                        (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
                      (PRN (-LRB- -LRB-)
                        (NP (NN PBMC))
                        (-RRB- -RRB-)))))))
            (CC and)
            (NP (JJ normal) (NN PBMC)))))
      (. .))))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
        (NP (JJ NF-κB) (NN activity))
        (PP (IN in)
          (NP
            (NP
              (NP (DT the) (NN absence))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 1))
                (-RRB- -RRB-)))
            (CC or)
            (NP
              (NP (NN presence))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 2))
                (-RRB- -RRB-)))
            (PP (IN of)
              (NP
                (NP (NN anti-CD3))
                (CC plus)
                (NP (JJ anti-CD28) (NN antibody)))))))
      (: ;)
      (NP
        (NP (NN supershift) (NN assay))
        (PP (IN of)
          (NP (JJ NF-κB) (NN site)))
        (PP (IN with)
          (NP
            (NP (NNS antibodies))
            (PP (IN against)
              (NP
                (NP
                  (NP (NN p65))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP lane) (CD 3))
                    (-RRB- -RRB-)))
                (, ,)
                (NP
                  (NP (NN p50))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP lane) (CD 4))
                    (-RRB- -RRB-)))
                (CC and)
                (NP
                  (NP (NN c-Rel))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP lane) (CD 5))
                    (-RRB- -RRB-))))))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (NN PBMC))
        (PP (IN from)
          (NP
            (NP (NNS patients))
            (PP (IN with)
              (NP (NN RA))))))
      (VP
        (VP (VBD were)
          (VP (VBN stimulated)
            (PP (IN with)
              (NP
                (NP (NN anti-CD3))
                (CC plus)
                (NP (NN anti-CD28))))))
        (CC and)
        (VP (VBD were)
          (VP (VBN used)
            (PP (IN for)
              (NP (DT the) (NN supershift) (NN assay)))))))
    (. .)))

(
  (S
    (NP
      (NP (-LRB- -LRB-) (NN b) (-RRB- -RRB-) (JJ NF-κB) (NN activity))
      (PP (IN in)
        (NP
          (NP
            (NP (DT the) (NN absence))
            (PRN (-LRB- -LRB-)
              (NP (NNP lane) (CD 1))
              (-RRB- -RRB-)))
          (CC or)
          (NP
            (NP (NN presence))
            (PRN (-LRB- -LRB-)
              (NP (NNP lane) (CD 2))
              (-RRB- -RRB-)))
          (PP (IN of)
            (NP
              (NP (JJ anti-CD3) (NN antibody))
              (CC plus)
              (NP (NN anti-CD28))))))
      (PP (IN in)
        (NP (JJ normal) (NN PBMC)))
      (. .))))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-))
        (NN NF-κB) (NN activity))
      (PP (IN in)
        (NP
          (NP
            (NP
              (NP (DT the) (NN absence))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 1))
                (-RRB- -RRB-)))
            (CC or)
            (NP
              (NP (NN presence))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 2))
                (-RRB- -RRB-))))
          (PP (IN of)
            (NP
              (NP
                (NP
                  (NP (NN anti-CD3))
                  (, ,)
                  (NP (NN anti-CD3))
                  (CC plus)
                  (NP (NN LY294002)))
                (PRN (-LRB- -LRB-)
                  (NP (NNP lane) (CD 3))
                  (-RRB- -RRB-)))
              (CC or)
              (NP
                (NP (NN anti-CD3))
                (CC plus)
                (NP
                  (NP (NN pyrrolidine) (NN dithiocarbamate))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN PDTC))
                      (: ;)
                      (NP (NNP lane) (CD 4)))
                    (-RRB- -RRB-))))))))
      (. .))))

(
  (S
    (S
      (NP (NNS Arrows))
      (VP (VB denote)
        (NP
          (NP (DT a) (JJ labeled) (NN oligonucleotide) (NN band))
          (VP (VBN shifted)
            (PP (IN after)
              (NP (NN NF-κB) (NN binding)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJR lower) (NN panel))
      (VP (VBZ shows)
        (NP
          (NP (DT an) (NN immunoblot))
          (PP (IN for)
            (NP
              (NP (NN IκB-α))
              (CC and)
              (NP (NN actin)))))
        (PP (IN at)
          (NP (DT the) (JJ same) (NN time)))))
    (. .)))

(
  (S
    (NP
      (NP (NN Table) (CD 1))
      (: :)
      (NP
        (NP (NN Production))
        (PP (IN of)
          (NP
            (NP (NN interleukin-17))
            (PP (IN in)
              (NP
                (NP (NN response))
                (PP (TO to)
                  (NP
                    (NP (NN anti-CD3))
                    (CC and)
                    (NP (NNS mitogens))))))))
        (PP (IN by)
          (NP
            (NP
              (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))
              (CC and)
              (NP (NN T) (NNS cells)))
            (PP (IN from)
              (NP
                (NP (NNS patients))
                (PP (IN with)
                  (NP (JJ rheumatoid) (NN arthritis)))))))))))

